1
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934
Filed by the registrant [X]
Filed by a party other than the registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only
(as permitted by Rule 14a-6(e)(2))
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
InSite Vision Incorporated
- --------------------------------------------------------------------------------
(NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
InSite Vision Incorporated
- --------------------------------------------------------------------------------
(NAME OF PERSON(S) FILING PROXY STATEMENT, IF OTHER THAN THE REGISTRANT)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1)
and 0-11.
(1) Title of each class of securities to which transaction applies:
- --------------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
- --------------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
- --------------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
- --------------------------------------------------------------------------------
(5) Total fee paid:
- --------------------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials.
- --------------------------------------------------------------------------------
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the form or schedule and the date of its filing.
- --------------------------------------------------------------------------------
(1) Amount Previously Paid:
- --------------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
- --------------------------------------------------------------------------------
(3) Filing Party:
- --------------------------------------------------------------------------------
(4) Date Filed:
- --------------------------------------------------------------------------------
2
[LOGO]
April 27, 1998
Dear Stockholder:
You are cordially invited to attend the 1998 Annual Meeting of Stockholders
of InSite Vision Incorporated (the "Company") to be held on Monday, June 8, 1998
at 11:00 a.m. local time at the Company's corporate headquarters, 965 Atlantic
Avenue, Alameda, California 94501. The formal Notice of Annual Meeting of
Stockholders and Proxy Statement accompanying this letter describe the business
to be acted upon.
Please sign, date and return your proxy card no later than May 15, 1998, in
the enclosed envelope, whether or not you plan to attend the meeting. If you
attend the meeting, you may still vote in person if you so desire.
Sincerely,
[LOGO]
S. Kumar Chandrasekaran, Ph.D.
Chairman of the Board and
Chief Executive Officer
YOUR VOTE IS IMPORTANT
SO THAT YOUR COMMON STOCK WILL BE REPRESENTED AT THE ANNUAL MEETING IN THE
EVENT YOU ARE NOT PERSONALLY PRESENT, PLEASE DATE, SIGN AND RETURN PROMPTLY THE
ENCLOSED PROXY IN THE ENVELOPE PROVIDED. EXECUTION OF THE PROXY WILL NOT AFFECT
YOUR RIGHT TO VOTE IN PERSON IF YOU ARE PRESENT AT THE MEETING.
3
INSITE VISION INCORPORATED
------------------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD JUNE 8, 1998
------------------------
TO THE STOCKHOLDERS OF INSITE VISION INCORPORATED:
NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders ("Annual
Meeting") of InSite Vision Incorporated, a Delaware corporation (the "Company"),
will be held on Monday, June 8, 1998, at 11:00 a.m. local time, at the Company's
corporate headquarters, 965 Atlantic Avenue, Alameda, California 94501, for the
following purposes:
1. To elect five directors to serve until the 1999 annual meeting or
until their respective successors are elected and qualified.
2. To approve a series of amendments to the Company's 1994 Stock
Option Plan (the "1994 Plan"), including (i) revisions to the Automatic
Option Grant Program for non-employee Board members under the 1994 Plan to
change the dates on which grants are to be made under the program and to
increase the number of shares for which such options are to be granted and
(ii) elimination of the 150,000-share limitation on the maximum number of
shares issuable under the Automatic Option Grant Program.
3. To ratify and approve the Company's issuance of 7,000 shares of
Series A Convertible Preferred Stock, and a warrant to purchase 70 shares
of Series A Convertible Preferred Stock, in a private placement effective
as of September 12, 1997.
4. To ratify the appointment of Ernst & Young LLP as the Company's
independent auditors for the fiscal year ending December 31, 1998.
5. To transact such other business as may properly come before the
Annual Meeting and any adjournment of the Annual Meeting.
The foregoing items of business are more fully described in the Proxy
Statement accompanying this Notice.
The Board of Directors has fixed the close of business on April 10, 1998,
as the record date for determining the stockholders entitled to receive notice
of and to vote at the Annual Meeting and any adjournment thereof. A complete
list of stockholders entitled to vote will be available from the Secretary of
the Company for 10 days before the Annual Meeting.
All stockholders are cordially invited to attend the Annual Meeting.
However, to assure your representation at the meeting, please carefully read the
accompanying Proxy Statement which describes the matters to be voted upon at the
Annual Meeting and mark, date, sign and return the enclosed proxy card in the
reply envelope provided. Should you receive more than one proxy because your
shares are registered in different names and addresses, each proxy should be
returned to ensure that all your shares will be voted. If you attend the Annual
Meeting and vote by ballot, your proxy vote will be revoked automatically and
only your vote at the Annual Meeting will be counted. The prompt return of your
proxy card will assist us in preparing for the Annual Meeting.
By Order of the Board of Directors,
[LOGO]
S. Kumar Chandrasekaran, Ph.D.
Chairman of the Board and
Chief Executive Officer
Alameda, California
April 27, 1998
4
INSITE VISION INCORPORATED
965 ATLANTIC AVENUE
ALAMEDA, CALIFORNIA 94501
------------------------
PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 8, 1998
GENERAL INFORMATION FOR STOCKHOLDERS
This Proxy Statement is furnished in connection with the solicitation by
the Board of Directors of InSite Vision Incorporated, a Delaware corporation
(the "Company"), with principal executive offices at 965 Atlantic Avenue,
Alameda, California 94501, of proxies in the accompanying form to be used at the
Annual Meeting of Stockholders ("Annual Meeting") to be held at 11:00 a.m. local
time on June 8, 1998, and any adjournment thereof.
This Proxy Statement and the accompanying form of proxy are being mailed to
all stockholders entitled to vote at the Annual Meeting on or about April 27,
1998.
RECORD DATE AND VOTING
Stockholders of record on April 10, 1998 (the "Record Date") are entitled
to notice of and, as described below, to vote at the Annual Meeting. As of the
Record Date, 14,411,402 shares of the Company's Common Stock, par value $0.01
per share (the "Common Stock"), were issued and outstanding, held by
approximately 211 stockholders of record or, as estimated by the Board,
approximately 6,000 beneficial stockholders. As of the Record Date, 4,357 shares
of the Company's Series A Convertible Preferred Stock ("Series A Stock") were
issued and outstanding, but no holder of Series A Stock is entitled to vote on
any matter coming before the Annual Meeting. Each stockholder is entitled to one
vote for each share of Common Stock held by such stockholder as of the Record
Date. If a choice as to the matters coming before the Annual Meeting has been
specified by a stockholder on the Proxy, such stockholder's shares will be voted
accordingly. If no choice is specified, the shares will be voted IN FAVOR OF the
approval of the proposals described in the Notice of Annual Meeting of
Stockholders and in this Proxy Statement. Abstentions and broker non-votes
(i.e., the submission of a Proxy by a broker or nominee specifically indicating
the lack of discretionary authority to vote on the matter) are counted for
purposes of determining the presence or absence of a quorum for the transaction
of business. Abstentions will be counted towards the tabulation of votes cast on
proposals presented to the stockholders and will have the same effect as
negative votes, whereas broker non-votes will not be counted for purposes of
determining whether a proposal has been approved or not.
Any stockholder or stockholder's representative who, because of a
disability, may need special assistance or accommodation to allow him or her to
participate at the Annual Meeting may request reasonable assistance or
accommodation from the Company by contacting Investor Relations in writing at
965 Atlantic Avenue, Alameda, California 94501 or by telephone at (510)
865-8800. To provide the Company sufficient time to arrange for reasonable
assistance, please submit such requests by May 15, 1998.
IMPORTANT
PLEASE MARK, DATE AND SIGN THE ENCLOSED PROXY CARD, AND RETURN IT AT YOUR
EARLIEST CONVENIENCE IN THE ENCLOSED, POSTAGE-PREPAID, RETURN ENVELOPE SO THAT,
IF YOU ARE UNABLE TO ATTEND THE ANNUAL MEETING, YOUR SHARES MAY BE VOTED.
5
REVOCABILITY OF PROXIES
Any person giving a proxy has the power to revoke it at any time prior to
or at the Annual Meeting. It may be revoked by filing with the Secretary of the
Company at the Company's principal executive offices, InSite Vision
Incorporated, 965 Atlantic Avenue, Alameda, California 94501, a notice of
revocation or another signed proxy with a later date. You may also revoke your
proxy by attending the Annual Meeting and voting in person.
SOLICITATION
The Company will bear the entire cost of solicitation, including the
preparation, assembly, printing and mailing of this Proxy Statement, the Proxy
and any additional solicitation materials furnished to stockholders. Copies of
solicitation materials will be furnished to brokerage houses, fiduciaries, and
custodians holding shares in their names that are beneficially owned by others
so that they may forward this solicitation material to such beneficial owners.
In addition, the Company may reimburse such persons for their costs in
forwarding the solicitation materials to such beneficial owners. The original
solicitation of proxies by mail may be supplemented by solicitation by telephone
or other means by directors, officers, employees or agents of the Company. The
Company will not pay any compensation to directors, officers or employees of the
Company and does not currently intend to retain a proxy solicitation agent,
however the Company may do so if necessary. The Company does not presently
intend to solicit proxies other than by mail.
THE COMPANY'S ANNUAL REPORT TO STOCKHOLDERS FOR THE YEAR ENDED DECEMBER 31,
1997 (THE "ANNUAL REPORT") AND ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED
DECEMBER 31, 1997 (THE "FORM 10-K") HAVE BEEN MAILED CONCURRENTLY WITH THE
MAILING OF THE NOTICE OF ANNUAL MEETING AND PROXY STATEMENT TO ALL STOCKHOLDERS
ENTITLED TO NOTICE OF AND TO VOTE AT THE ANNUAL MEETING. NEITHER THE ANNUAL
REPORT NOR THE FORM 10-K IS INCORPORATED INTO THIS PROXY STATEMENT AND NEITHER
IS CONSIDERED PROXY SOLICITING MATERIAL.
MATTERS TO BE CONSIDERED AT THE ANNUAL MEETING
PROPOSAL ONE -- ELECTION OF DIRECTORS
The Bylaws of the Company provide that the Board of Directors shall be
comprised of not less than five nor more than nine directors. Effective
immediately prior to the Annual Meeting, the authorized number of directors will
be five. Such directors will stand for re-election at the Annual Meeting to
serve until the Company's next annual meeting, until their successors shall have
been duly elected and qualified, or until their earlier death, resignation or
removal. Mr. Grant M. Inman resigned from the Board effective April 1, 1998, and
his vacancy on the Board will not be filled prior to or at the Annual Meeting.
However, Mr. Inman will continue to serve the Company as a consultant. In
addition, Mr. John S. Saxe a former member of the Board, continues to serve the
Company as "Director Emeritus." The Board of Directors will vote all proxies
received by them in favor of the five nominees listed below unless otherwise
instructed in writing on such proxy. If, however, any of the nominees named in
the accompanying proxy card are unable or unwilling to serve (which is not
expected) at the time of the Annual Meeting, the proxies (except those marked to
the contrary) will be voted for such other person(s) as the persons named in the
accompanying proxy may recommend. The five candidates receiving the highest
number of affirmative votes of the shares represented and voting at the Annual
Meeting will be elected directors of the Company.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE
ELECTION OF EACH OF THE FOLLOWING NOMINEES TO SERVE AS DIRECTORS OF THE COMPANY
UNTIL THE 1999 ANNUAL MEETING, UNTIL THEIR RESPECTIVE SUCCESSORS HAVE BEEN
ELECTED AND QUALIFIED OR UNTIL THEIR EARLIER DEATH, RESIGNATION OR REMOVAL.
2
6
Set forth below is information regarding the nominees, including
information furnished by them as to their principal occupation at present and
for the last five years, certain other directorships held by them, the year in
which each became a director of the Company, and their ages as of April 10,
1998:
DIRECTOR
NOMINEES POSITION(S) WITH THE COMPANY AGE SINCE
-------- ---------------------------- --- --------
S. Kumar Chandrasekaran, Ph.D Chairman of the Board and 54 1989
Chief Executive Officer
Mitchell H. Friedlaender, M.D Director 52 1996
John E. Lucas Director 66 1996
John L. Mattana Director 68 1997
Anders P. Wiklund Director 58 1996
BUSINESS EXPERIENCE OF BOARD NOMINEES
S. KUMAR CHANDRASEKARAN, PH.D., has been a Director of the Company since
1989. Dr. Chandrasekaran joined the Company in September 1987 as Vice President,
Development. From 1988 to 1989, Dr. Chandrasekaran served as Vice President,
Research and Development. From 1989 to 1993, Dr. Chandrasekaran served as
President and Chief Operating Officer. Since August 1993, he has served as
Chairman of the Board of Directors and Chief Executive Officer and from December
1995 to December 1997 he served as Chief Financial Officer. Prior to joining the
Company, Dr. Chandrasekaran was Vice President of Technical Affairs for Sola
Barnes Hind (formerly Syntex Ophthalmics) from 1982 to 1987. From 1971 to 1982,
he served as a Principal Scientist and director at Alza Corporation. Dr.
Chandrasekaran holds a Ph.D. in Chemical Engineering from the University of
California at Berkeley.
MITCHELL H. FRIEDLAENDER, M.D. has been a Director of the Company since May
1996. He has served as an ophthalmologist at Scripps Clinic and Research
Foundation ("Scripps") since 1986 and currently serves as director of Cornea and
Refractive Surgery in the Division of Ophthalmology. Prior to joining Scripps,
Dr. Friedlaender served as a full-time faculty member at the University of
California, San Francisco for 10 years. He is the founder of the Aspen Corneal
Society and the Pacific Ophthalmic Forum, co-editor in chief of International
Ophthalmology Clinics, a member of four scientific editorial boards, a member of
the Sjogren's Syndrome Foundation Medical Advisory Board, and former president
of the Ocular Microbiology and Immunology Group. He also serves as a consultant
for several pharmaceutical companies and performs clinical studies on new
ophthalmic drugs. Dr. Friedlaender holds an M.B.A. from the University of
Phoenix and an M.D. from the University of Michigan.
JOHN E. LUCAS has been a Director of the Company since May 1996. He served
as President and Chief Executive Officer of American Scientific Resources Ltd.
from 1994 to March 1996, and as President and Chief Executive Officer of
Oxigene, Inc. from 1991 to 1994. He also was the co-founder and served as
Chairman and Chief Executive Officer of XOMA Corporation. Mr. Lucas holds an
M.B.A. from Harvard Business School.
JOHN L. MATTANA has been a Director of the Company since September 1997.
From 1992 to 1997 Mr. Mattana served as an Investment Vice President at New York
Life Insurance Company, where he was a Director of Venture Capital Investment.
From October 1997 to December 1997 he also served as a Vice President at Ceptor
Corporation. He holds an M.B.A. from New York University.
ANDERS P. WIKLUND has been a Director of the Company since October 1996.
Since January 1997 he has served as Principal at Wiklund International Inc., an
advisory firm to the biotechnology and pharmaceutical industries. He served as
Vice President, Corporate Business Development of Pharmacia & Upjohn from
January to December 1996, as Executive Vice President of Pharmacia U.S. Inc.
from January to December 1995 and as President and Director of Pharmacia
Development Corp. from 1993 to 1994. Mr. Wiklund served as Chief Executive
Officer, President and Director of Kabi Pharmacia Inc. from 1984 to 1993. Mr.
Wiklund serves on the board of directors of Ribozyme Pharmaceuticals Inc., Trega
Biosciences Inc., Vascular Therapeutics and Medivir AB, and is a Senior Vice
President at Biacore Holding Inc. Mr. Wiklund holds a Master of Pharmacy from
the Pharmaceutical Institute, Stockholm, Sweden.
3
7
BOARD COMMITTEES AND MEETINGS
During the fiscal year ended December 31, 1997, the Board of Directors held
seven meetings and acted by unanimous written consent twice. The Board of
Directors has an Audit Committee, a Stock Plan and Compensation Committee and a
Nominating Committee.
The Audit Committee currently consists of one director, Anders P.
Wiklund.(1) The Audit Committee held two meetings during the 1997 fiscal year.
The Audit Committee monitors the effectiveness of the internal and external
audit controls, oversees the Company's financial and accounting organization and
financial reporting, and selects a firm of certified public accountants whose
duty it is to audit the books and accounts of the Company for the fiscal year
for which they are appointed.
The Stock Plan and Compensation Committee (the "Compensation Committee")
currently consists of one director, Anders P. Wiklund.(1) The Compensation
Committee held three meetings during the 1997 fiscal year and acted by unanimous
written consent three times. The Compensation Committee determines and reviews
the compensation to be paid to the Company's officers and directors and
administers the Company's 1994 Stock Option Plan (the "1994 Plan") and the 1994
Employee Stock Purchase Plan (the "ESPP").
The Nominating Committee consists of one director, S. Kumar Chandrasekaran,
Ph.D.(1) The Nominating Committee held no meetings during the 1997 fiscal year.
The Nominating Committee, on behalf of the Board of Directors, makes nominations
for election to the Company's Board of Directors. The Nominating Committee will
consider nominations recommended by stockholders. Such nominations by
stockholders must be made by notice in writing delivered or mailed by first
class United States mail, postage prepaid, to the Secretary or Assistant
Secretary of the Company, and received by the Secretary or Assistant Secretary
not less than 120 days prior to any meeting of stockholders called for the
election of directors, provided, however, that if less than 100 days' notice of
the meeting is given to stockholders, such nomination shall have been mailed or
delivered to the Secretary or Assistant Secretary of the Company not later than
the close of business on the seventh day following the day on which the notice
of the meeting was mailed. Such notice shall set forth as to each proposed
nominee who is not an incumbent director (i) the name, age, business address
and, if known, residence address of each nominee proposed in such notice, (ii)
the principal occupation or employment of each such nominee, (iii) the number of
shares of stock of the Company which are beneficially owned by each such nominee
and by the nominating stockholder, and (iv) any other information concerning the
nominee that must be disclosed of nominees in proxy solicitations regulated by
Regulation 14A of the Securities Exchange Act of 1934, as amended.
During the 1997 fiscal year no currently serving director attended fewer
than 75% of the aggregate number of meetings of the Board of Directors and
meetings of the Committees of the Board of Directors on which he served for the
time period during which he held a position as director.
- ---------------
(1) Grant M. Inman served on each committee until April 1, 1998. New members of
each committee may be appointed following the election of directors at the
1998 Annual Meeting of Stockholders.
COMPENSATION OF DIRECTORS
Each non-employee Board member who is not otherwise affiliated with a
substantial investor in the Company is eligible to receive $1,000 for each Board
meeting and $250 for each committee meeting attended in person, together with
reimbursement of expenses for attending such meetings.
Under the Automatic Option Grant Program in effect under the 1994 Plan,
each individual who first joins the Board as a non-employee Board member will
receive, at the time of his or her initial election or appointment to the Board,
an option grant to purchase 10,000 shares of Common Stock at an exercise price
per share equal to the fair market value per share of Common Stock on the grant
date. Each such option will have a maximum term of 10 years measured from the
grant date, subject to earlier termination upon the optionee's cessation of
Board service, and will become exercisable for all of the option shares upon the
optionee's completion of one year of Board service measured from such grant
date. However, the option will immediately become exercisable for all the option
shares upon certain changes in control of the Company. On
4
8
September 15, 1997, the effective date of his appointment to the Board, John L.
Mattana received such a 10,000-share option grant under the Automatic Option
Grant Program with an exercise price per share of $4.75, the fair market value
per share of Common Stock on such grant date.
Each individual serving as a non-employee Board member on December 15, 1997
received an option grant under the amended Automatic Option Grant Program to
purchase 10,000 shares of Common Stock at an exercise price of $2.813 per share,
the fair market value per share of Common Stock on such grant date. These option
grants are subject to stockholder approval at the Annual Meeting. If such
stockholder approval is obtained, then in December of each year, beginning in
December 1998, each individual continuing to serve as a non-employee Board
member will receive an automatic option grant to purchase 10,000 shares of
Common Stock, provided such individual member did not receive his or her initial
grant within the preceding six months. Each option will have an exercise price
per share equal to the fair market value per share of Common Stock on the grant
date. All such options, including the December 1997 grants, will have a maximum
term of 10 years measured from the grant date, subject to earlier termination
upon the optionee's cessation of Board service. The options will become
exercisable upon the optionee's completion of one year of Board service,
measured from the grant date. However, the options will immediately become
exercisable upon certain changes in control of the Company. For further
information concerning the December 1997 option grants and the revisions to the
Automatic Option Grant Program, please see "Proposal Two -- Amendments to 1994
Stock Option Plan" below.
On June 2, 1997, in accordance with the Automatic Option Grant Program in
effect under the 1994 Plan, each individual elected as a non-employee Board
member at the Company's 1997 Annual Meeting of Stockholders held on that date
received an option grant to purchase 5,000 shares of Common Stock at an exercise
price of $6.234 per share, the fair market value per share of Common Stock on
that date.
On December 13, 1996, the Company entered into a consulting agreement with
John E. Lucas, a non-employee Board member, pursuant to which Mr. Lucas serves
as a special advisor and consultant to the Company in the fields of public
relations, mergers and acquisitions and other special assignments. In exchange
for such consulting services, the Company pays Mr. Lucas a consulting fee in the
amount of $3,900 per month.
On November 1, 1996, the Company entered into a consulting agreement with
Anders P. Wiklund, a non-employee Board member, pursuant to which Mr. Wiklund
serves as an advisor and consultant in the field of business development. In
exchange for such consulting services, the Company pays Mr. Wiklund a consulting
fee in the amount of $5,000 per month.
On December 1, 1997, the Company entered into a deferred compensation
consulting agreement with John L. Mattana, a non-employee Board Member, pursuant
to which Mr. Mattana serves as an advisor and consultant in the field of
investor relations. In exchange for such consulting services, the Company
accrues $2,500 per month, payable to Mr. Mattana in January 2002.
PROPOSAL TWO -- AMENDMENTS TO 1994 STOCK OPTION PLAN
APPROVAL OF AMENDMENTS TO THE
INSITE VISION INCORPORATED 1994 STOCK OPTION PLAN
Stockholders are being asked to approve a series of amendments to the 1994
Plan which the Company's Board of Directors (the "Board") authorized on December
15, 1997. The amendments will effect the following changes to the Automatic
Option Grant Program in effect for non-employee Board members under the 1994
Plan:
(i) change the date on which the annual option grants are to be made
to continuing non-employee Board members from the date of each Annual
Stockholders Meeting to the date of the first Board meeting held in
December each year, beginning with the option grants made on December 15,
1997; provided, however, that for any year in which there is no December
Board meeting, the annual grants for that year will be made on December
15th or (if December 15th is not a trading day) the immediately succeeding
trading day;
5
9
(ii) increase the number of shares of Common Stock for which option
grants are to be made annually to the continuing non-employee Board members
from 5,000 shares to 10,000 shares, effective with the December 15, 1997
option grants;
(iii) except for the December 15, 1997 option grants, impose the
requirement that a non-employee Board member will be eligible to receive an
annual 10,000-share option grant only if that individual did not receive
his or her initial 10,000-share option grant within the preceding six (6)
months; and
(iv) eliminate the provisions of the 1994 Plan which impose a
150,000-share limitation on the maximum number of shares issuable under the
Automatic Option Grant Program.
The changes to the Automatic Option Grant Program will provide the Company
with the opportunity to offer a more meaningful equity incentive program to
attract and retain the services of non-employee Board members. Stockholder
approval of this Proposal will also constitute approval of the 10,000-share
option grants made to each of the following non-employee Board members under the
amended Automatic Option Grant Program on December 15, 1997: Dr. Friedlaender
and Messrs. Inman, Lucas, Mattana and Wiklund. Each such option has an exercise
price per share of $2.813.
The 1994 Plan was originally adopted by the Board as the 1993 Stock Plan,
which became effective on October 25, 1993. The name of the 1993 Stock Plan was
changed to the 1994 Stock Option Plan, effective January 1, 1994. The 1993 Stock
Plan was the successor to the 1989 Stock Option Plan ("1989 Option Plan"), and
all outstanding options under the 1989 Option Plan have been incorporated into
the 1994 Plan.
The purpose of the 1994 Plan is to provide eligible employees, non-employee
Board members and consultants the opportunity to acquire a proprietary interest,
or otherwise increase their proprietary interest, in the Company as an incentive
for them to remain in the service of the Company or its subsidiaries.
The principal terms and provisions of the 1994 Plan as modified by the
recent amendments approved by the Board, together with the applicable tax and
accounting implications, are summarized below. The summary is not, however,
intended to be a complete description of all the terms of the Plan. A copy of
the Plan will be furnished without charge to any stockholder upon written
request to the Corporate Secretary at the Company's principal executive office
in Alameda, California.
EQUITY INCENTIVE PROGRAMS
The 1994 Plan consists of two separate equity incentive programs: (i) a
Discretionary Option Grant Program, under which officers and other employees,
non-employee Board members and independent consultants may, at the discretion of
the Plan Administrator, be granted stock options to purchase shares of Common
Stock at an exercise price per share equal to the fair market value of the
option shares on the grant date, and (ii) an Automatic Grant Program, under
which option grants will be made at specified intervals to non-employee Board
members.
Options granted under the Discretionary Option Grant Program may be either
incentive stock options designed to meet the requirements of Section 422 of the
Internal Revenue Code or non-statutory options not intended to satisfy such
requirements. All grants under the Automatic Option Grant Program will be non-
statutory options.
SHARE RESERVE
As of April 3, 1998, a total of 2,754,374 shares of Common Stock were
reserved for issuance over the remainder of the 10 year term of the 1994 Plan.
The number of shares of Common Stock available for issuance under the 1994 Plan
automatically increases on the first day of January each year by an amount equal
to 2% of the number of shares of Common Stock outstanding on the last day of
December in the immediately preceding year. The shares issuable under the 1994
Plan may be drawn from either authorized but previously unissued shares of stock
or from reacquired shares of stock, including shares purchased by the Company on
the open market.
6
10
Should an option expire or terminate for any reason prior to exercise in
full (including options cancelled in accordance with the cancellation-regrant
provisions of the 1994 Plan), the shares subject to the portion of the option
not so exercised will be available for subsequent issuance under the 1994 Plan.
However, any shares surrendered to pay the exercise price of an outstanding
option or shares withheld to pay any taxes associated with the exercise of the
option will not be available for subsequent issuance under the 1994 Plan.
The maximum number of shares for which any one individual participating in
the 1994 Plan may be granted stock options and separately exercisable stock
appreciation rights may not exceed 850,000 shares in the aggregate over the term
of the 1994 Plan. However, for purposes of this limitation, any option grants or
stock appreciation rights made on or before December 31, 1993 will not be taken
into account.
PLAN ADMINISTRATION
The 1994 Plan (other than the Automatic Option Grant Program) is
administered by the Stock Plan and Compensation Committee ("Committee" or the
"Plan Administrator") of the Board. The Committee is comprised of two or more
non-employee Board members appointed by the Board. The Committee, acting as Plan
Administrator, has complete discretion (subject to the express provisions of the
1994 Plan) to authorize stock option grants and stock appreciation rights under
the 1994 Plan. However, all grants under the Automatic Option Grant Program will
be made in strict compliance with the express provisions of that program, and no
administrative discretion will be exercised by the Plan Administrator with
respect to the grants made under such program.
ELIGIBILITY
Officers and other key employees who render services that contribute to the
management, growth and financial success of the Company, non-employee members of
the Board and independent consultants in the service of the Company or any
parent or subsidiary corporation (whether now existing or subsequently
established) are eligible to participate in the Discretionary Option Grant
Program. Non-employee Board members are also eligible to participate in the
Automatic Option Grant Program.
As of April 3, 1998, four non-employee Board members (excluding Grant M.
Inman who resigned from the Board as of April 1, 1998), three executive officers
and approximately forty-four other employees were eligible to participate in the
1994 Plan. The four non-employee Board members were also eligible to participate
in the Automatic Option Grant Program.
VALUATION
The fair market value per share of Common Stock on any relevant date under
the 1994 Plan is the closing selling price per share on the date in question as
reported on the Nasdaq National Market. If there is no reported closing price
for such date, then the closing price for the last previous date for which such
quotation exists will be determinative of such fair market value. On April 3,
1998, the fair market value per share of Common Stock determined on such basis
was $3.983.
DISCRETIONARY OPTION GRANT PROGRAM
The principal features of the Discretionary Option Grant Program may be
summarized as follows:
The exercise price per share will be set by the Plan Administrator, but in
no event will the exercise price be less than 100% of the fair market value per
share of stock on the grant date. No option will have a maximum term in excess
of 10 years measured from the grant date. Options issued under the Discretionary
Option Grant Program may become exercisable in cumulative increments over a
period of months or years as determined by the Plan Administrator.
The exercise price may be paid in cash or in shares of Common Stock valued
at fair market value on the exercise date. Each option may also be exercised
through a same-day sale program pursuant to which a designated brokerage firm is
to effect an immediate sale of the shares purchased under the option and pay to
7
11
the Company, out of the sales proceeds available on the settlement date,
sufficient funds to cover the exercise price for the purchased shares plus all
applicable withholding taxes.
Loans
The Plan Administrator may also assist any optionee (including an officer)
in the exercise of outstanding options under the Discretionary Option Grant
Program by authorizing a loan from the Company or permitting the optionee to pay
the exercise price in installments over a period of years. The terms and
conditions of any such loan or installment payment will be established by the
Plan Administrator in its sole discretion, but in no event may the maximum
credit extended to the optionee exceed the aggregate exercise price payable for
the purchased shares (less the par value of those shares) plus any Federal,
state or local income taxes or employment taxes incurred by the optionee in
connection with the option exercise.
Limited Stock Appreciation Rights
Each officer of the Company subject to the short-swing profit restrictions
of the Federal securities laws will be granted a limited stock appreciation
right as part of any stock option grant made to such officer under the
Discretionary Option Grant Program. Any option with such a limited stock
appreciation right may be surrendered to the Company upon the successful
completion of a hostile tender offer for securities possessing more than 50% of
the combined voting power of the Company's outstanding securities. In return for
the surrendered option, the officer will be entitled to a cash distribution from
the Company in an amount per surrendered option share equal to the excess of (a)
the highest reportable price per share of stock paid in such hostile tender
offer over (b) the exercise price payable for such share.
Cessation of Service
Outstanding options under the Discretionary Option Grant Program will
terminate, with respect to any shares for which such options are exercisable at
the time of the optionee's cessation of service with the Company, within three
months following such cessation of service (or 12 months in the case of
cessation of service due to permanent disability), unless the Plan Administrator
determines that such exercise period should be further extended for one or more
additional months or years. Under no circumstances, however, may any such option
remain exercisable after the specified expiration date of the option term.
Should the optionee die while holding one or more exercisable options, then
those options will remain exercisable for a 12-month period measured from the
earlier of (i) the date of the optionee's death or (ii) the date of the
optionee's cessation of service and may be exercised within that period by the
personal representative of the optionee's estate or by the persons to whom such
options are transferred by the optionee's will or by the laws of inheritance.
During the applicable exercise period following the optionee's cessation of
service, the option may not be exercised for more than the number of option
shares for which the option is exercisable at the time of such cessation of
service. However, the Plan Administrator will have the discretionary authority
to accelerate, in whole or in part, the exercisability of any outstanding
options held by the optionee and may exercise this discretion at any time while
the option remains outstanding.
For purposes of the 1994 Plan, the optionee will be deemed to be in the
service of the Company for so long as such individual renders periodic services
to the Company or any parent or subsidiary, whether as an employee, a
non-employee member of the Board or an independent consultant or advisor.
Stockholder Rights/Limited Transferability
The optionee does not have any stockholder rights with respect to the
option shares until the option is exercised and the exercise price is paid for
the purchased shares. Options are generally not assignable or transferable other
than by will or the laws of inheritance and, during the optionee's lifetime, the
option may be exercised only by such optionee. However, the Plan Administrator
may allow non-statutory options to be transferred or assigned during the
optionee's lifetime to one or more members of the optionee's immediate
8
12
family or to a trust established exclusively for one or more such family
members, to the extent such transfer or assignment is in furtherance of the
optionee's estate plan.
Tax Withholding
The Plan Administrator may in its discretion provide one or more option
holders under the Discretionary Option Grant Program with the election to have
the Company withhold, from the shares of Common Stock otherwise issuable upon
the exercise of their options, a portion of those shares with an aggregate fair
market value equal to the designated percentage (up to 100% as specified by the
option holder) of the Federal, state and local income and employment tax
liability incurred by such option holder in connection with the exercise of such
option. Any election so made will be subject to the approval of the Plan
Administrator. One or more option holders may also be granted the alternative
right, subject to Plan Administrator approval, to deliver previously-issued
shares of Common Stock in satisfaction of such tax liability.
Cancellation -- Regrant of Options
The Plan Administrator has the authority to effect, on one or more separate
occasions, the cancellation of outstanding options under the Discretionary
Option Grant Program which have exercise prices in excess of the then current
market price of stock and to issue replacement options with an exercise price
not less than the market price of stock at the time of the new grant.
AUTOMATIC GRANT PROGRAM
Each individual who first joins the Board as a non-employee Board member
will, at the time of his or her initial election or appointment to the Board,
automatically be granted an option to purchase 10,000 shares of Common Stock.
However, a non-employee Board member who replaces a Board member will not
receive an initial 10,000-share grant if both the new and former Board members
are affiliated with the same investment fund or similar entity. If the
stockholders approve this Proposal, then the 150,000-share limitation previously
in effect for the maximum number of shares of Common Stock issuable to
non-employee Board members under the Automatic Option Grant Program will be
eliminated. In addition, such stockholder approval will also constitute approval
of the 10,000-share option grant made under the program on December 15, 1997 to
each individual serving as a non-employee Board member at that time and the
subsequent exercise of that option in accordance with the provisions of the
Automatic Option Grant Program. Each such grant has an exercise price of $2.813
per share.
Under the amended Automatic Option Grant Program, an option grant for
10,000 shares of Common Stock will automatically be made at the first Board
meeting in December each year, beginning December 1998, to each individual
continuing to serve as a non-employee Board member, provided such individual did
not receive his or her initial 10,000-share option grant within the preceding
six (6) months. In the event there is no December Board meeting in any year,
then the annual option grant for that year will be made on December 15th or (if
December 15th is not a day on which the New York Stock Exchange is open for
business) such grant will be made on the immediately succeeding trading day.
Stockholder approval of this Proposal will constitute pre-approval of each
option subsequently granted pursuant to the provisions of the Automatic Option
Grant Program summarized below and the subsequent exercise of that option in
accordance with such provisions.
The exercise price per share for each automatic grant will be the fair
market value per share of Common Stock on the date of grant and will be payable
in cash or shares of Common Stock. The option may also be exercised through a
cashless exercise procedure pursuant to which a designated brokerage firm
effects an immediate sale of the shares purchased under the option and pays to
the Company, out of the sales proceeds available on the settlement date,
sufficient funds to cover the exercise price for the purchased shares plus all
applicable withholding taxes.
Each automatic option grant will become exercisable for all the option
shares upon the optionee's completion of one year of Board service following the
grant date. However, full and immediate vesting and
9
13
exercisability of the option will occur upon a Corporate Transaction and Change
in Control (as such terms are defined in the section below entitled
"Acceleration of Options").
Automatic Option Cancellation
Each automatic option grant will be automatically cancelled upon a hostile
take-over of the Company effected through a tender offer for securities
possessing more than 50% of the combined voting power of the Company's
outstanding securities. In return the optionee will be entitled to a cash
distribution from the Company in an amount equal to the excess per share of (i)
the highest reportable per share price paid in the hostile tender offer over
(ii) the exercise price payable for each such share subject to the surrendered
option, whether or not the option is otherwise at the time exercisable for all
the option shares. Stockholder approval of this Proposal will also constitute
pre-approval of each option subsequently granted with such an automatic
cancellation provision and the subsequent cancellation of that option in
accordance with such provision. No additional approval of the Plan Administrator
or the Board will be required at the time of the actual option cancellation and
cash distribution.
Cessation of Board Service
Upon cessation of Board service, the options held by the non-employee Board
member will remain exercisable for three months (or six months if cessation of
Board service is due to permanent disability). Should the optionee die while
holding one or more options, then those options may subsequently be exercised by
the personal representative of the optionee's estate or by the persons to whom
such options are transferred by the optionee's will or by the laws of
inheritance within six months of the director's death. During such post-service
exercise period, the option may not be exercised for more than the number of
option shares for which the option is exercisable at the time of the optionee's
cessation of Board service.
GENERAL PROVISIONS
ACCELERATION OF OPTIONS
Outstanding options under the 1994 Plan will become immediately exercisable
in the event of certain changes in the ownership or control of the Company.
Corporate Transaction
In the event of any of the following stockholder-approved transactions in
which the Company is a party (a "Corporate Transaction"):
(a) a merger or consolidation in which securities possessing more than
50% of the total combined voting power of the Company's outstanding
securities are transferred to a person or persons different from the
persons holding those securities immediately prior to such transaction, or
(b) the sale, transfer or other disposition of all or substantially
all of the Company's assets in complete liquidation or dissolution of the
Company,
each outstanding option under the 1994 Plan will automatically become
exercisable for all of the option shares, unless the option is either to be
assumed by the successor corporation (or its parent corporation) in such
Corporate Transaction or is otherwise to be replaced with a comparable option to
purchase shares of the capital stock of the successor corporation. Upon the
consummation of the Corporate Transaction, all outstanding options under the
1994 Plan will terminate and cease to be exercisable, except to the extent
assumed by the successor corporation.
10
14
Change in Control
In the event of a Change in Control (as defined below), each outstanding
option under the 1994 Plan will automatically become exercisable for all of the
option shares. A Change in Control will be deemed to have occurred if:
(i) any person or related group of persons (other than the Company or
a person that directly or indirectly controls, is controlled by, or is
under common control with, the Company) directly or indirectly acquires
beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act)
of securities possessing 40% or more of the total combined voting power of
the Company's outstanding securities pursuant to a tender or exchange offer
made directly to the Company's stockholders which the Board does not
recommend such stockholders to accept; or
(ii) the composition of the Board changes over a period of two
consecutive years or less such that a majority of the Board members ceases
to be comprised of individuals who either (A) have been Board members
continuously since the beginning of such period or (B) have been elected or
nominated for election as Board members during such period by at least a
three-fourths ( 3/4) majority of the Board members described in clause (A)
who were still in office at the time such election or nomination was
approved by the Board.
Upon a Change in Control, all outstanding options will remain exercisable
until the expiration or sooner termination of the option term specified in the
instrument evidencing the option.
The acceleration of the exercisability of options in the event of a
Corporate Transaction or Change in Control may be seen as an anti-takeover
provision and may have the effect of discouraging a merger proposal, a takeover
attempt or other efforts to gain control of the Company.
CHANGES IN CAPITALIZATION
In the event any change is made to the outstanding shares of stock by
reason of any recapitalization, stock dividend, stock split, combination of
shares, exchange of shares or other change in corporate structure effected
without the Company's receipt of consideration, appropriate adjustments will be
made to (i) the maximum number and/or class of securities issuable under the
1994 Plan, (ii) the maximum number and/or class of securities for which any one
individual may be granted stock options and separately exercisable stock
appreciation rights under the 1994 Plan after December 31, 1993, (iii) the
number and/or class of securities and price per share in effect under each
outstanding option (including all option grants incorporated from the 1989
Option Plan) and (iv) the maximum number of shares issuable under the Automatic
Option Grant Program to newly-elected or continuing non-employee Board members.
Each outstanding option which is assumed or is otherwise to continue in
effect after a merger or business combination will be appropriately adjusted to
apply and pertain to the number and class of securities which would have been
issuable, in connection with such merger or business combination, to an actual
holder of the same number of shares of Common Stock as are subject to such
option immediately prior to such merger or business combination. Appropriate
adjustments will also be made to the option price payable per share and to the
number and class of securities available for issuance under the 1994 Plan.
Option grants under the 1994 Plan will not affect the right of the Company
to adjust, reclassify, reorganize or otherwise change its capital or business
structure or to merge, consolidate, dissolve, liquidate or sell or transfer all
or any part of its business or assets.
AMENDMENT AND TERMINATION
The Board may amend or modify the 1994 Plan in any or all respects
whatsoever. However, no such amendment may adversely affect the rights of
existing optionees holding outstanding options without their consent. In
addition, certain amendments may require stockholder approval pursuant to
applicable laws or regulations. The Board may terminate the 1994 Plan at any
time, and the 1994 Plan will in all events terminate on the earlier of (i) July
27, 2003, or (ii) the date all shares available for issuance are issued or
11
15
cancelled. Each stock option outstanding at the time of such termination will
remain in force in accordance with the provisions of the instruments evidencing
such grant.
STOCK AWARDS
The table below shows, as to each of the Company's officers listed in the
Summary Compensation Table set forth elsewhere in this Proxy Statement (the
"Named Executive Officers") and the various indicated individuals and groups,
the following information with respect to stock option transactions under the
1994 Plan from January 1, 1997 to April 3, 1998: (i) the number of shares of
stock subject to options granted during that period and (ii) the weighted
average option price payable per share.
OPTION TRANSACTIONS
WEIGHTED AVERAGE
OPTIONS GRANTED EXERCISE PRICE
NAME (NUMBER OF SHARES) OF OPTIONS GRANTED
---- ------------------ ------------------
S. Kumar Chandrasekaran, Ph.D................... 250,000 $3.75
Lyle M. Bowman, Ph.D............................ 15,000 $3.75
Michael D. Baer................................. 50,000 $3.75
All executive officers as a group who received
option grants (3 persons)..................... 315,000 $3.75
All current non-employee directors as a group
who received option grants (5 persons)*....... 80,000 $3.91
All employees, including current officers who
are not Named Executive Officers, as a group
who received option grants (approximately 19
persons)...................................... 163,500 $4.25
- ---------------
* Includes option grants totalling 15,000 shares to Mr. Inman.
FEDERAL INCOME TAX CONSEQUENCES
OPTION GRANTS
Options granted under the 1994 Plan may be either incentive stock options
which satisfy the requirements of Section 422 of the Internal Revenue Code or
non-statutory options which are not intended to meet such requirements. The
federal income tax treatment for the two types of options differs as described
below:
Incentive Options. No taxable income is recognized by the optionee at the
time of the option grant, and no taxable income is generally recognized at the
time the option is exercised. The optionee will, however, recognize taxable
income in the year in which the purchased shares are sold or otherwise made the
subject of disposition. For federal tax purposes, dispositions are divided into
two categories: (i) qualifying and (ii) disqualifying. The optionee will make a
qualifying disposition of the purchased shares if the sale or other disposition
of such shares is made after the optionee has held the shares for more than two
years after the grant date of the option and more than one year after the
exercise date. If the optionee fails to satisfy either of these two minimum
holding periods prior to the sale or other disposition of the purchased shares,
then a disqualifying disposition will result.
Upon a qualifying disposition of the shares, the optionee will recognize
long-term capital gain in an amount equal to the excess of (i) the amount
realized upon the sale or other disposition of the purchased shares over (ii)
the exercise price paid for those shares. If there is a disqualifying
disposition of the shares, then the excess of (i) the fair market value of those
shares on the option exercise date over (ii) the exercise price paid for the
shares will be taxable as ordinary income. Any additional gain recognized upon
the disposition will be a capital gain.
If the optionee makes a disqualifying disposition of the purchased shares,
then the Company will be entitled to an income tax deduction, for the taxable
year in which such disposition occurs, equal to the excess
12
16
of (i) the fair market value of such shares on the option exercise date over
(ii) the exercise price paid for the shares. In no other instance will the
Company be allowed a deduction with respect to the optionee's disposition of the
purchased shares.
Non-Statutory Options. No taxable income is recognized by an optionee upon
the grant of a non-statutory option. The optionee will in general recognize
ordinary income, in the year in which the option is exercised, equal to the
excess of the fair market value of the purchased shares on the exercise date
over the exercise price paid for the shares, and the optionee will be required
to satisfy the tax withholding requirements applicable to such income.
The Company will be entitled to an income tax deduction equal to the amount
of ordinary income recognized by the optionee with respect to the exercised
non-statutory option. The deduction will in general be allowed for the taxable
year of the Company in which such ordinary income is recognized by the optionee.
STOCK APPRECIATION RIGHTS
An optionee who is granted a stock appreciation right will recognize
ordinary income in the year of exercise equal to the amount of the appreciation
distribution. The Company will be entitled to an income tax deduction equal to
the appreciation distribution for the taxable year in which the ordinary income
is recognized by the optionee.
DEDUCTIBILITY OF EXECUTIVE COMPENSATION
The Company anticipates that any compensation deemed paid by it in
connection with disqualifying dispositions of incentive stock option shares or
exercises of non-statutory options will, to the extent those incentive stock
options or non-statutory options were granted prior to January 1, 1997, qualify
as performance-based compensation for purposes of Code Section 162(m) and will
not have to be taken into account for purposes of the $1 million limitation per
covered individual on the deductibility of the compensation paid to certain
executive officers of the Company. However, any compensation deemed paid by the
Company in connection with transactions relating to stock options granted during
the 1997 fiscal year will be subject to such $1 million limitation.
ACCOUNTING TREATMENT
Option grants with exercise prices equal to 100% of the fair market value
of the shares on the grant date will not result in a compensation expense to the
Company's earnings. However, the Company must disclose, in footnotes to the
Company's financial statements, the impact those options would have upon the
Company's reported earnings were the value of those options treated as
compensation expense. The number of outstanding options may be a factor in
determining the Company's earnings per share on a fully-diluted basis.
The grant of stock appreciation rights that require certain conditions to
be satisfied before the right may be exercised, such as the occurrence of a
hostile tender offer, will not result in a compensation expense to the Company's
earnings.
NEW PLAN BENEFITS
The 10,000-share option grants which Dr. Friedlaender and Messrs. Inman,
Lucas, Mattana and Wiklund each received under the amended Automatic Option
Grant Program on December 15, 1997 are contingent upon stockholder approval of
this Proposal and will not become exercisable in whole or in part unless such
stockholder approval is obtained. Each such option has an exercise price per
share of $2.813, the fair market value per share of Common Stock on the grant
date.
STOCKHOLDER APPROVAL
The affirmative vote of a majority of the outstanding shares of the
Company's voting Common Stock present or represented at the 1998 Annual Meeting
and entitled to vote on the Proposal is required for approval of the amendments
to the 1994 Plan. If such stockholder approval is not obtained, the revisions to
the
13
17
Automatic Option Program which would change the dates on which grants are to be
made under that program and increase the number of shares for which such options
are to be granted would not be implemented, and the 10,000-share option grants
made to the non-employee Board members on December 15, 1997 would terminate
without ever becoming exercisable for any of the option shares. In the absence
of such stockholder approval, the 150,000-share limitation on the maximum number
of shares issuable under the Automatic Option Grant Program would remain in
effect. However, option grants may continue to be made pursuant to the
provisions of the 1994 Plan in effect immediately prior to the amendments
summarized in this Proposal, until the available reserve of Common Stock as last
approved by the stockholders has been issued pursuant to option grants made
under the 1994 Plan. Accordingly, non-employee Board members re-elected at the
1998 Annual Meeting would each receive an option grant for 5,000 shares under
the Automatic Option Grant Program in lieu of their December 15, 1997 grants.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE
APPROVAL OF THE AMENDMENTS TO THE 1994 PLAN.
PROPOSAL THREE
APPROVAL OF ISSUANCE OF SERIES A CONVERTIBLE PREFERRED STOCK
Stockholders are being asked to ratify and approve the Company's issuance
in September 1997 of 7,000 shares of Series A Convertible Preferred Stock, par
value $0.01 per share ("Series A Stock"), to a group of five investors (the
"Series A Investors") at a per share price of $1,000 and the issuance of a
warrant to purchase 70 shares of Series A Stock at an exercise price of $1,000
per share to the Placement Agent for such transaction (the "Series A Issuance").
The rules of the Nasdaq National Market System require stockholder approval
prior to the sale or issuance of designated securities (common stock or
securities convertible into or exercisable for common stock), in connection with
a transaction other than a public offering, equal to 20% or more of the common
stock or 20% or more of the voting power outstanding before the issuance for
less than the greater of book or market value of the stock. The Series A Stock
is convertible into shares of the Company's Common Stock, trading on the Nasdaq
National Market System, at a ratio equal to (i) the aggregate stated value of
the shares of Series A Stock then being converted ($1,000 per share) plus a
premium in the amount of 6% per annum accruing from September 12, 1997 through
the date of conversion, divided by (ii) a conversion price (the "Conversion
Price") equal to the lower of $2.127 or the product of the average of the lowest
closing bid prices for the Common Stock for any five (5) trading days during the
twenty-two (22) consecutive trading day period immediately preceding the date of
conversion multiplied by a conversion percentage equal to (A) 90% if the
conversion occurs prior to June 10, 1998, (B) 87.5% if the conversion occurs on
or after June 10, 1998 and prior to September 13, 1998, (C) 85% if the
conversion occurs on or after September 13, 1998 and prior to December 7, 1998,
or (D) 82.5% if the conversion occurs on or after December 7, 1998.
Consequently, the Series A Stock was sold in the Series A Issuance at a price
which, on an as-converted basis, represented a discount from the Common Stock's
market price as of the date the Series A Stock was issued.
Stockholder approval was not required prior to the Series A Issuance
because the terms of the transaction prohibited each Series A Investor from
converting its shares of Series A Stock if such conversion would cause the
aggregate amount of Series A Stock converted by such Investor to exceed such
Investor's pro rata portion of that number of shares equal to 20% or more of the
Company's Common Stock outstanding at the time of the Series A Issuance (the
"Cap Amount"). However, the Company agreed to use its best efforts to obtain
stockholder approval at the Annual Meeting in order to remove the Cap Amount
limitation.
If this proposal is not approved and any Series A Investor is unable to
convert its shares of Series A Stock because such a conversion would exceed its
pro rata portion of the Cap Amount, each Series A Investor will have the right
to require the Company to redeem its shares of Series A Stock which, on an
as-converted basis, exceed its pro rata portion of the Cap Amount. Such a
redemption would be for cash at a premium over the purchase price of (i) 6% per
annum accruing from September 12, 1997 through the date of redemption and (ii) a
multiplier equal to the highest closing bid price of the Company's Common Stock
during the period between receipt of a redemption notice and payment of the
redemption amount divided by the Conversion
14
18
Price. As of the record date of the Annual Meeting, a total of 4,357 shares of
Series A Stock were outstanding, with an approximate redemption value of (i)
$2,489,000 in excess of the Cap Amount and (ii) $7,152,000 in the aggregate. The
redemption value in excess of the Cap Amount may be less until September 12,
2000 given that no Series A Investor, together with its affiliates, may
beneficially own more than 4.9% of the Company's then outstanding Common Stock
prior to that date.
If the Company is unable to effect the redemption of any amounts in excess
of each pro rata portion of the Cap Amount, then (i) all Series A Stock will be
subject to redemption, (ii) any Series A Investor having provided a notice to
the Company requiring redemption will be entitled to interest on the amount to
be redeemed at an annual rate equal to the lower of 24% or the highest interest
rate permitted by applicable law from the date of the redemption request until
the redemption payment is made, (iii) such a Series A Investor will be entitled
to convert the interest accrued, as well as the amount to be redeemed, into
shares of Common Stock at the lowest Conversion Price in effect during the
period of non-redemption and (iv) any Series A Investor which is unable to
convert its Series A Stock because such conversion would exceed that Investor's
pro rata portion of the Cap Amount will have the right, with the consent of
holders of at least 50% of the then outstanding shares of Series A Stock, to
require the Company to delist its Common Stock from the Nasdaq National Market
System and instead make its Common Stock eligible for trading on the Nasdaq
SmallCap Market or the over-the-counter electronic bulletin board (the "OTC").
In addition, failure to effect such a redemption would result in a permanently
reduced Conversion Price for the Series A Stock such that any future conversion,
when available to the Series A Investors, would cause greater dilution to the
holders of Common Stock. There can be no assurance that the Company would be
able to make any redemption payments due (even those only in excess of the Cap
Amount), and any such payments would have a substantial negative impact on the
Company's cash flow and could severely restrict the Company's ability to finance
its research and development and continue operations. Furthermore, the
additional remedies available to the Series A Investors described above could
result in reduced marketability of the Company's shares and further dilution to
the Company's stockholders.
The affirmative vote of the holders of a majority of the Company's shares
entitled to vote present in person or represented by proxy at the Annual Meeting
is required to approve this Proposal.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE
FOR THE RATIFICATION AND APPROVAL OF THE SERIES A ISSUANCE.
PROPOSAL FOUR -- RATIFICATION OF INDEPENDENT ACCOUNTANTS
The Board of Directors has appointed the firm of Ernst & Young LLP,
independent accountants, to audit the financial statements of the Company for
the fiscal year ending December 31, 1998, and is asking the stockholders to
ratify this appointment.
In the event the stockholders fail to ratify the appointment, the Board of
Directors will reconsider its selection. Even if the selection is ratified, the
Board of Directors in its discretion may direct the appointment of a different
independent accounting firm at any time during the year if the Board of
Directors believes that such a change would be in the best interests of the
Company and its stockholders. The affirmative vote of the holders of a majority
of the Company's voting shares represented and voting at the Annual Meeting is
required to ratify the selection of Ernst & Young LLP.
Ernst & Young LLP has audited the Company's financial statements annually
since 1986. A representative of Ernst & Young LLP is expected to be present at
the Annual Meeting, will have the opportunity to make a statement if he or she
desires to do so, and will be available to respond to appropriate questions.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE
FOR THE RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP TO SERVE AS
THE COMPANY'S INDEPENDENT ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31,
1998.
15
19
EXECUTIVE COMPENSATION AND RELATED INFORMATION
COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION
The Compensation Committee of the Board is responsible for establishing the
cash and equity compensation of the Company's Chief Executive Officer, Dr.
Chandrasekaran, and the Company's other executive officers. All decisions by the
Compensation Committee with respect to cash compensation are reviewed by the
full Board of Directors. However, the Compensation Committee has the sole and
exclusive authority to administer the Company's 1994 Stock Option Plan (the
"1994 Plan") and to make option grants to the Company's executive officers under
the 1994 Plan. The Compensation Committee has furnished the following report
with respect to the 1997 compensation of Dr. Chandrasekaran and the Company's
other executive officers.
Compensation Policy
The Compensation Committee's principal goals in making its executive
compensation recommendations are (i) to ensure that there exists an appropriate
relationship between executive pay and both the operating performance of the
Company and stockholder value, particularly, but not exclusively, as reflected
in the price of the Company's Common Stock, and (ii) to attract, motivate and
retain key executives in the face of competition within the biopharmaceutical
industry for qualified personnel. To achieve these objectives, the Compensation
Committee's executive compensation policies generally integrate annual base
salaries and other guaranteed payments for Dr. Chandrasekaran and the Company's
other executive officers with variable incentive bonuses and stock options
primarily based upon corporate and individual performance. In addition to
linking executive compensation directly to stockholder value, the Compensation
Committee believes that stock options, through staged vesting provisions,
perform an important role in motivating and retaining key executives.
Performance is measured primarily by comparison with specific objectives.
Base Salary
The base salary levels for the executive officers were established for the
1997 fiscal year on the basis of the following factors: personal performance,
the estimated salary levels in effect for similar positions at a select group of
companies with which the Company competes for executive talent, and internal
comparability considerations. The Compensation Committee, however, did not rely
upon any specific compensation surveys for comparative compensation purposes.
Instead, the Compensation Committee made its decisions as to the appropriate
market level of base salary for each executive officer on the basis of its
understanding of the salary levels in effect for similar positions at those
companies with which the Company competes for executive talent. The Compensation
Committee estimates that the base salary levels in effect for the Company's
executive officers were at the median of the salary levels in effect for similar
positions at those competitor companies. Base salaries will be reviewed on an
annual basis, and adjustments will be made in accordance with the factors
indicated above.
Performance Measures
Due to the current stage of the Company's development, the Compensation
Committee believes that corporate performance is not appropriately measured in
terms of traditional financial performance criteria such as profitability and
earnings per share. Rather, the Compensation Committee believes that corporate
performance is appropriately measured by analyzing the degree to which the
Company has achieved certain goals established by the Compensation Committee and
approved by the Board. Accordingly, annual incentive compensation is awarded on
the basis of these non-traditional factors.
The incentive compensation paid to the executive officers for the 1997
fiscal year was based primarily upon the Company's attainment of performance
milestones tied to clinical and regulatory developments and the pursuit and
formation of third-party collaborative relationships with respect to the
Company's technology. The bonuses awarded to the executive officers on the basis
of the Company's achievement of those milestones are reflected in the Summary
Compensation Table which appears later in this Proxy Statement.
16
20
Stock Option Grants
Stock option grants under the 1994 Plan are designed to align the interests
of each executive officer with those of the stockholders and provide each
individual with a significant incentive to manage the Company from the
perspective of an owner with an equity stake in the business. Each grant allows
the individual to acquire shares of Common Stock at a fixed price per share (the
market price on the grant date) over a specified period of time (up to 10
years). Each option generally becomes exercisable in installments over a period
of years, contingent upon the executive officer's continued employment with the
Company. Accordingly, the option will provide a return to the executive officer
only if the executive officer remains employed by the Company during the
applicable vesting period, and then only if the market price of the underlying
shares appreciates over the option term.
The number of shares subject to each option grant will be set at a level
intended to create a meaningful opportunity for stock ownership based on the
officer's current position with the Company, the base salary associated with
that position, the size of comparable awards made to individuals in similar
positions within the industry, the individual's potential for increased
responsibility and promotion over the option term, and the individual's personal
performance in recent periods. The Compensation Committee will also take into
account the executive officer's existing holdings of Common Stock and the number
of vested and unvested options held by that individual in order to maintain an
appropriate level of equity incentive. However, the Compensation Committee does
not intend to adhere to any specific guidelines as to the relative option
holdings of the Company's executive officers.
The option grants made to the executive officers during the 1997 fiscal
year were intended to provide such individuals with a meaningful incentive to
remain in the Company's employ and to contribute to the Company's financial
success in the form of stock price appreciation.
CEO Compensation
In setting the total compensation payable to Dr. Chandrasekaran, the
Company's Chief Executive Officer, for the 1997 fiscal year, the Compensation
Committee sought to make such compensation competitive with that provided by
other companies with which the Company competes for executive talent.
The base salary paid to Dr. Chandrasekaran for the 1997 fiscal year was not
based to any significant extent on Company performance. Instead, it is the
Committee's intent to have this component of his compensation remain stable from
year to year. For the 1997 fiscal year, the Committee estimates that Dr.
Chandrasekaran's base salary was at the median level of base salaries paid to
the chief executive officers of other companies with which the Company competes
for executive talent. The incentive portion of Dr. Chandrasekaran's cash
compensation for the 1997 fiscal year was based solely on the Company's
attainment of performance milestones. Those milestones were tied to clinical and
regulatory developments and the pursuit and formation of third-party
collaborative relationships with respect to the Company's technology and were
the same milestones used to measure the incentive compensation payable to the
other executive officers for the 1997 fiscal year.
The stock option granted to Dr. Chandrasekaran for the 1997 fiscal year
reflected the Committee's continuing policy to maintain his option holdings at a
level competitive with that of other chief executive officers in the industry
and to subject a portion of his compensation each year to the market performance
of the Company's common stock. Accordingly, the stock option grant will be of no
value to Dr. Chandrasekaran unless he continues in the Company's employ and the
market price of the Company's common stock appreciates over his period of
continued employment.
Compliance with Internal Revenue Code Section 162(m)
Section 162(m) of the Internal Revenue Code, enacted in 1993, generally
disallows a tax deduction to publicly held companies for compensation exceeding
$1 million paid to certain of the corporation's executive officers. The
limitation applies only to compensation which is not considered to be
performance-based. The non-performance based compensation to be paid to the
Company's executive officers for the 1997 fiscal year
17
21
did not exceed the $1 million limit per officer, nor is it expected that the
non-performance based compensation to be paid to the Company's executive
officers for fiscal 1998 will exceed that limit. In addition, the option grants
made under the 1994 Plan prior to January 1, 1997 have been structured so that
any compensation deemed paid to an executive officer in connection with the
exercise of those grants will qualify as performance-based compensation which
will not be subject to the $1 million limitation. However, any compensation
deemed paid by the Company in connection with transactions relating to options
granted during the 1997 fiscal year will have to be taken into account for
purposes of the $1 million limitation. Because it is very unlikely that the
compensation payable to any of the Company's executive officers in the
foreseeable future will approach the $1 million limit, the Compensation
Committee has decided at this time not to take any action to limit or
restructure the elements of compensation payable to the Company's executive
officers. The Compensation Committee will reconsider this decision should the
individual compensation of any executive officer ever approach the $1 million
level.
Grant M. Inman
Anders P. Wiklund
18
22
PERFORMANCE GRAPH
The following graph compares the monthly percentage change in (i) the
cumulative total stockholder return on the Company's Common Stock from October
18, 1993, the date of the Company's initial public offering, through December
31, 1997 with (ii) the cumulative total return on (a) The Nasdaq Stock Market
(U.S. Index) and (b) the Nasdaq Biotech Index. The comparison assumes (i) an
investment of $100 on October 18, 1993 in each of the foregoing indices and (ii)
reinvestment of dividends, if any. THE STOCK PRICE PERFORMANCE SHOWN ON THE
GRAPH BELOW REPRESENTS HISTORICAL PRICE PERFORMANCE AND IS NOT NECESSARILY
INDICATIVE OF ANY FUTURE STOCK PRICE PERFORMANCE.
Measurement Period NASDAQ NASDAQ Biotech
(Fiscal Year Covered) Insite Vision Composite Index
10/19/93 100.00 100.00 100.00
86.67 99.36 98.67
Dec-93 93.33 101.05 98.06
102.22 104.13 103.84
87.78 102.59 89.88
Mar-94 73.33 96.72 77.84
60.00 95.46 77.40
61.11 95.68 78.64
Jun-94 56.67 91.84 72.00
57.78 93.94 75.41
54.44 98.73 84.19
Sep-94 52.22 99.43 83.81
48.89 101.14 81.07
46.67 96.34 81.17
Dec-94 42.22 97.82 79.98
40.00 98.24 83.94
35.56 103.01 86.33
Mar-95 28.89 106.31 85.57
26.67 109.79 88.69
24.44 113.02 89.29
Jun-95 27.78 121.43 100.01
40.00 130.25 109.08
37.78 132.62 122.27
Sep-95 41.67 135.75 126.27
32.22 135.25 120.96
19.44 137.28 128.40
Dec-95 31.67 136.87 150.80
54.44 137.87 162.42
64.44 141.29 157.76
Mar-96 48.89 143.28 150.71
54.44 154.87 157.04
58.89 161.14 162.16
Jun-96 51.11 154.16 146.03
42.22 140.57 132.34
38.89 148.60 139.79
Sep-96 38.89 159.61 151.81
36.67 158.90 147.20
40.00 169.09 146.54
Dec-96 53.33 167.95 150.31
44.44 179.50 163.93
36.67 170.57 166.89
Mar-97 38.33 158.93 145.73
40.56 164.01 138.48
Jun-97 55.42 182.75 157.31
48.89 187.60 153.24
45.56 207.34 158.35
Sep-97 42.78 210.49 156.59
41.11 219.29 169.51
34.44 207.31 159.30
Dec-97 31.11 211.90 158.16
28.89 204.28 150.21
21.11 210.66 149.69
Mar-98 31.11 228.78 155.07
30.00 238.80 167.74
Notwithstanding anything to the contrary set forth in any of the Company's
previous filings under the Securities Act of 1933, as amended, or the Exchange
Act, which might incorporate future filings made by the Company under those
statutes, the preceding Compensation Committee Report on Executive Compensation
and the Company Stock Performance Graph will not be incorporated by reference
into any of those prior filings, nor will such report or graph be incorporated
by reference into any future filings made by the Company under those Acts.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Compensation Committee, until April 1, 1998, consisted of Grant M.
Inman and Anders P. Wiklund. A replacement for Mr. Inman will be elected
following the Annual Meeting. No member of the Compensation Committee was at any
time during the 1997 fiscal year, or at any other time, an officer or employee
of the Company.
During the 1997 fiscal year, no executive officer of the Company served as
a member of the board of directors or compensation committee of any entity which
has one or more executive officers serving as a member of the Company's Board of
Directors or Compensation Committee.
19
23
EMPLOYMENT CONTRACTS AND CHANGE OF CONTROL ARRANGEMENTS
On May 30, 1995, the Company amended the 1994 Plan to implement a special
change in control feature designed to protect the economic benefit of the
outstanding options in the event the Company were to be acquired. As a result of
this special feature, should an optionee's service be involuntarily terminated
within twelve (12) months following a Corporate Transaction in which his or her
options are assumed by the successor corporation or parent thereof and do not
otherwise accelerate at that time, then those options will accelerate and become
fully exercisable for all of the option shares as fully-vested shares of Common
Stock upon such involuntary termination. A "Corporate Transaction" under the
1994 Plan is defined as a merger or consolidation in which securities possessing
more than 50% of the total combined voting power of the Company's outstanding
securities are transferred to a person or persons different from those who held
those securities immediately prior to such transaction, or the sale, transfer or
other disposition of all or substantially all of the Company's assets in
complete liquidation of the Company. "Involuntary Termination" is defined under
the 1994 Plan as the optionee's involuntary dismissal or discharge by the
Company for reasons other than misconduct, or the optionee's voluntary
resignation following (a) a change in his or her position with the Company which
materially reduces his or her responsibilities or (b) a reduction in his or her
level of compensation (including base salary, fringe benefits and any
non-discretionary and objective-standard incentive payment or bonus award) by
more than 15% or (c) a relocation of the optionee's place of employment by more
than 50 miles, and such change, reduction or relocation is effected by the
Company without the optionee's consent.
SUMMARY OF CASH AND CERTAIN OTHER COMPENSATION
The following table sets forth the compensation earned by the Company's
Chief Executive Officer, and each of the Company's other executive officers
whose salary and bonus for fiscal year 1997 was in excess of $100,000, for
services rendered in all capacities to the Company for the 1997, 1996 and 1995
fiscal years (the "Named Executive Officers"). No executive officer who would
have otherwise been included in such table on the basis of salary and bonus
earned for the 1997 fiscal year resigned or terminated employment during that
fiscal year.
SUMMARY COMPENSATION TABLE
LONG-TERM
COMPENSATION
ANNUAL COMPENSATION AWARDS
----------------------------------------- SECURITIES ALL
OTHER ANNUAL UNDERLYING OTHER
NAME AND PRINCIPAL POSITION(1) YEAR SALARY($) BONUS($)(2) COMPENSATION($) OPTIONS/(#) COMPENSATION
- ------------------------------ ---- --------- ----------- --------------- ------------ ------------
S. Kumar Chandrasekaran, Ph.D 1997 302,000 -- 3,150(3) -- --
Chairman of the Board and 1996 262,000 50,000 2,592(3) -- --
Chief Executive Officer 1995 247,400 25,000 21,414(3) 225,000 --
Lyle M. Bowman, Ph.D 1997 164,000 -- 967(4) -- --
Vice President, Development 1996 154,445 15,000 901(4) -- --
and Operations 1995 134,300 15,000 761(4) 60,000 --
Michael D. Baer 1997 154,000 -- 1,486(4) -- --
Chief Financial Officer and 1996 84,854 15,000 38,806(5) -- --
Vice President of Finance 1995 -- -- 58,506(5) -- --
- ---------------
(1) Principal Position determined as of December 31, 1997.
(2) The amounts shown under the Bonus column include cash bonuses earned for the
indicated fiscal years.
(3) Until June 1995, any vacation accrued above a two year period was paid out
quarterly. In 1995 Dr. Chandrasekaran received $3,980 for unused vacation
benefits. In 1997, 1996 and 1995, the premiums paid by the Company to
provide Dr. Chandrasekaran with excess life insurance coverage were $3,150,
$2,592 and $2,424, respectively. In addition, $15,010 was paid to Dr.
Chandrasekaran in 1995 as a 1994 salary adjustment.
(4) Represents amounts paid for excess life insurance coverage.
(5) The 1996 amount includes excess life insurance coverage in the amount of
$806 and fees totaling $38,000 received as an independent contractor. The
1995 amount consists only of independent contracting fees in the amount of
$58,506.
20
24
OPTION/SAR GRANTS
The following table contains information concerning the grant of stock
options under the Plan to the Named Executive Officers during the 1997 fiscal
year. No stock appreciation rights were granted to the Named Executive Officers
during the 1997 fiscal year, except for the limited stock appreciation rights
described in footnote (2) below which form part of each option grant made to
them.
OPTION/SAR GRANTS IN LAST FISCAL YEAR
INDIVIDUAL GRANTS POTENTIAL REALIZABLE
----------------------------------------------------- VALUE AT ASSUMED
NUMBER OF % OF TOTAL ANNUAL RATES OF STOCK
SECURITIES OPTIONS PRICE APPRECIATION FOR
UNDERLYING GRANTED TO EXERCISE OPTION TERM(1)
OPTIONS/SARS EMPLOYEES IN PRICE EXPIRATION ----------------------
NAME GRANTED(#) FISCAL YEAR ($/SHARE) DATE 5% 10%
---- ------------ ------------ --------- ---------- -------- ----------
Michael D. Baer.......... 50,000(2) 10% $3.75 10/26/07 $117,877 $ 298,700
Lyle M. Bowman, Ph.D..... 15,000(2) 3% $3.75 10/26/07 $ 35,363 $ 89,610
S. Kumar Chandrasekaran,
Ph.D................... 250,000(2) 52% $3.75 10/26/07 $589,385 $1,493,499
- ---------------
(1) Potential realizable value is based on assumption that the market price of
the Common Stock appreciates at the annual rate shown (compounded annually)
from the date of grant until the end of the 10-year option term. There can
be no assurance that the actual stock price appreciation over the 10-year
option term will be at the assumed 5% and 10% levels or at any other defined
level.
(2) The option has a maximum term of 10 years, subject to earlier termination in
the event of the optionee's cessation of service with the Company. The
option will become exercisable for 25% of the option shares upon the
optionee's completion of one year of service measured from the October 27,
1997 grant date and for the balance in equal daily installments over the
next three years of service thereafter. However, the option will become
immediately exercisable for all the option shares upon an acquisition of the
Company by merger or asset sale, unless the option is assumed by the
successor entity. The option, to the extent so assumed, will subsequently
vest in full should the optionee's employment be terminated (whether
involuntarily or through a resignation following a material change in the
optionee's duties and responsibilities, level of compensation or principal
place of employment) within twelve (12) months following the acquisition in
which that option does not otherwise vest on an accelerated basis. The
option includes a limited stock appreciation right which will result in the
cancellation of that option, to the extent exercisable for vested shares,
upon the successful completion of a hostile tender offer for securities
possessing more than 50% of the combined voting power of the Company's
outstanding voting securities. In return for the cancelled option, the
optionee will receive a cash distribution per cancelled option share equal
to the excess of (i) the highest price paid per share of the Company's
Common Stock in such hostile tender offer over (ii) the exercise price
payable per share under the cancelled option. The exercise price may be paid
in cash or in shares of Common Stock (valued at fair market value on the
exercise date) or through a cashless exercise procedure involving a same-day
sale of the purchased shares. The Company may also finance the option
exercise by loaning the optionee sufficient funds to pay the exercise price
for the purchased shares and the federal and state income tax liability
incurred by the optionee in connection with such exercise.
OPTION EXERCISES AND HOLDINGS
The following table sets forth information concerning the exercise of
options during the 1997 fiscal year by the Company's Chief Executive Officer and
each of the Company's Named Executive Officers and the unexercised options held
by such individuals at the end of such fiscal year. No stock appreciation rights
were
21
25
exercised by such individuals during the 1997 fiscal year, and no outstanding
stock appreciation rights were held by them at the end of such fiscal year,
except for the special limited stock appreciation rights described in footnote
(2) to the Option/SAR Grant table which form part of each option grant made to
such executive officers.
AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR
AND FISCAL YEAR-END OPTION VALUES
NUMBER OF VALUE OF UNEXERCISED
SECURITIES UNDERLYING IN-THE-MONEY
UNEXERCISED OPTIONS AT OPTIONS AT
NUMBER OF AGGREGATE DECEMBER 31, 1997 DECEMBER 31, 1997(1)
SHARES ACQUIRED VALUE --------------------------- ---------------------------
NAME ON EXERCISE REALIZED($) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
---- --------------- ----------- ----------- ------------- ----------- -------------
S. Kumar Chandrasekaran,
Ph.D....................... -- -- 296,666 475,000 $786,165 $112,500
Michael D. Baer.............. -- -- 35,630 80,042 $ -- $ --
Lyle M. Bowman............... -- -- 75,165 75,000 $201,837 $ 30,000
- ---------------
(1) Calculated on the basis of the closing sale price per share of the Common
Stock on the Nasdaq National Market of $3.25 on December 31, 1997.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), requires the Company's directors and executive officers, and
persons who beneficially own more than 10% of a registered class of the
Company's equity securities, to file with the United States Securities and
Exchange Commission (the "SEC") initial reports of beneficial ownership and
reports of changes in beneficial ownership of Common Stock and other equity
securities of the Company. Officers, directors and greater than 10% stockholders
are required by SEC regulation to furnish the Company with copies of all Section
16(a) reports they file.
Based solely upon review of the copies of such reports furnished to the
Company and written representations that no other reports were required, the
Company believes that during the fiscal year ended December 31, 1997, its
officers, directors and holders of more than 10% of the Common Stock complied
with all Section 16(a) filing requirements.
22
26
PRINCIPAL STOCKHOLDERS
The following table sets forth certain information regarding beneficial
ownership of the Company's Common Stock, as of March 19, 1998, by (i) each
person who is known by the Company to beneficially own more than five percent of
the Company's Common Stock, (ii) the Chief Executive Officer and each of the
other executive officers of the Company named in the Summary Compensation Table,
(iii) each director and nominee for director at the Annual Meeting, and (iv) all
current executive officers and directors as a group. Except as otherwise
indicated, the Company believes that each of the beneficial owners of the Common
Stock listed below has sole investment power with respect to such shares,
subject to community property laws, where applicable.
BENEFICIALLY OWNED(1)(11)
------------------------------------
NAME OF BENEFICIAL OWNER NUMBER OF SHARES PERCENT OF CLASS
------------------------ ---------------- ----------------
New York Life Insurance Company(2).................... 1,132,813 7.86%
51 Madison Avenue
New York, NY 10010-1603
General Motors Investment Management Corporation(3)... 1,007,902 6.99%
767 5th Avenue
New York, NY 10153
S. Kumar Chandrasekaran, Ph.D.(4)..................... 345,694 2.35%
Lyle M. Bowman, Ph.D.(5).............................. 89,998 *
Michael D. Baer(6).................................... 35,630 *
Mitchell H. Friedlaender, M.D.(7)..................... 10,000 *
Grant M. Inman(8)..................................... 20,000 *
John E. Lucas(9)...................................... 33,000
John L. Mattana....................................... 0 *
Anders P. Wiklund(10)................................. 10,000 *
All current executive officers and directors as a
group (8 persons)................................... 544,322 3.78%
- ---------------
* Less than one percent of the outstanding Common Stock.
(1) Percentage of beneficial ownership is calculated assuming 14,411,402 shares
of Common Stock were outstanding on March 19, 1998. This percentage also
includes Common Stock of which such individual or entity has the right to
acquire beneficial ownership within 60 days of March 19, 1998, including
but not limited to upon the exercise of options; however, such Common Stock
shall not be deemed outstanding for the purpose of computing the percentage
owned by any other individual or entity. Such calculation is required by
General Rule 13d-3(1)(i) under the Exchange Act.
(2) Pursuant to a Schedule 13G dated February 12, 1997, filed with the
Securities and Exchange Commission, New York Life Insurance Company
reported that as of December 31, 1996 it had sole voting power and sole
dispositive power of all 1,132,813 shares. No filing has been made
subsequent to that date, so the Company assumes that the holdings of New
York Life Insurance Company remained the same as of December 31, 1997.
(3) Pursuant to an Amendment 1 to Schedule 13G dated February 20, 1998, filed
with the Securities and Exchange Commission, General Motors Investment
Management Corporation reported that as of December 31, 1997 it had shared
voting power and shared dispositive power of its 1,007,902 shares. This
number includes 503,951 shares held by Mellon Bank, N.A. as Trustee for the
General Motors Hourly-Rate Employee Pension Trust and 503,951 shares held
by Mellon Bank, N.A. as Trustee for the General Motors Salaried Employee
Pension Trust.
(4) Includes 296,666 shares issuable upon the exercise of stock options
exercisable on March 19, 1998 or within 60 days thereafter.
(5) Includes 75,165 shares issuable upon the exercise of stock options
exercisable on March 19, 1998 or within 60 days thereafter.
23
27
(6) Includes 35,360 shares issuable upon the exercise of stock options
exercisable on March 19, 1998 or within 60 days thereafter.
(7) Comprised of 10,000 shares issuable upon the exercise of stock options
exercisable on March 19, 1998 or within 60 days thereafter.
(8) Includes 10,000 shares issuable upon the exercise of stock options
exercisable on March 19, 1998 or within 60 days thereafter.
(9) Includes 10,000 shares issuable upon the exercise of stock options
exercisable on March 19, 1998 or within 60 days thereafter.
(10) Comprised of 10,000 shares issuable upon the exercise of stock options
exercisable on March 19, 1998 or within 60 days thereafter.
(11) Information presented regarding beneficial ownership of the Company's
Common Stock is as of March 19, 1998, the most recent practicable date for
which data is reasonably available to the Company.
ANNUAL REPORT AND FORM 10-K
A copy of the Annual Report of the Company for the fiscal year ended
December 31, 1997 (the "Annual Report") and the Annual Report on Form 10-K for
the fiscal year ended December 31, 1997 (the "Form 10-K"), as filed with the
Securities and Exchange Commission, have been mailed concurrently with this
Proxy Statement to all stockholders entitled to notice of and to vote at the
Annual Meeting. Neither the Annual Report nor the Form 10-K is incorporated into
this Proxy Statement and neither is considered proxy soliciting material.
OTHER MATTERS
Proposals of stockholders of the Company which are intended to be presented
by such stockholders at the Company's annual meeting of stockholders in 1999
must be received by the Company no later than December 28, 1998 in order that
they may be included in the proxy statement and form of proxy relating to that
meeting.
The Company knows of no other matters that will be presented for
consideration at the Annual Meeting. If any other matters properly come before
the Annual Meeting, it is the intention of the persons named in the enclosed
form of proxy to vote the shares they represent as the Board of Directors may
recommend. Discretionary authority with respect to such other matters is granted
by the execution of the enclosed proxy.
THE BOARD OF DIRECTORS
Dated: April 27, 1998
24
28
INSITE VISION INCORPORATED
1994 STOCK OPTION PLAN
(Amended and Restated as of December 15, 1997)
ARTICLE ONE
GENERAL PROVISIONS
I. PURPOSES OF THE PLAN
A. The 1994 Stock Option Plan (the "Plan") was adopted as the
1993 Stock Plan as of July 28, 1993 to be effective October 25, 1993 (the
"Effective Date") to promote the interests of InSite Vision Incorporated, a
Delaware corporation (the "Corporation"), by providing eligible individuals with
the opportunity to acquire a proprietary interest, or otherwise increase their
proprietary interest, in the Corporation as an incentive for them to remain in
the service of the Corporation (or its parent or subsidiary corporations). This
amendment and restatement changes the name of the Plan to the 1994 Stock Option
Plan and is effective as of December 15, 1997.
B. This Plan serves as the successor to the Corporation's 1989
Stock Plan (the "1989 Plan"), and no further option grants shall be made under
the 1989 Plan from and after the Effective Date. All options outstanding under
the 1989 Plan on such Effective Date are hereby incorporated into this Plan and
shall accordingly be treated as outstanding options under this Plan. However,
each outstanding option so incorporated shall continue to be governed solely by
the express terms and conditions of the instrument evidencing such grant, and no
provision of this Plan shall be deemed to affect or otherwise modify the rights
or obligations of the holders of such incorporated options with respect to their
acquisition of shares of the Corporation's common stock thereunder or their
exercise of any outstanding stock appreciation rights thereunder.
C. For purposes of the Plan, the following provisions shall be
applicable in determining the parent and subsidiary corporations of the
Corporation:
Any corporation (other than the Corporation) in an
unbroken chain of corporations ending with the Corporation shall be
considered to be a PARENT corporation of the Corporation, provided each
such corporation in the unbroken chain (other than the Corporation)
owns, at the time of the determination, stock possessing fifty percent
(50%) or more of the total combined voting power of all classes of stock
in one of the other corporations in such chain.
29
Each corporation (other than the Corporation) in an
unbroken chain of corporations beginning with the Corporation shall be
considered to be a SUBSIDIARY of the Corporation, provided each such
corporation (other than the last corporation) in the unbroken chain
owns, at the time of the determination, stock possessing fifty percent
(50%) or more of the total combined voting power of all classes of stock
in one of the other corporations in such chain.
II. STRUCTURE OF THE PLAN
A. The Plan shall be divided into two separate components: the
Discretionary Option Grant Program specified in Article Two and the Automatic
Option Grant Program specified in Article Three. Under the Discretionary Option
Grant Program, eligible individuals may be granted options to purchase shares of
the Corporation's common stock. Under the Automatic Option Grant Program, each
eligible member of the Corporation's Board of Directors (the "Board") will
automatically receive an option grant to purchase shares of the Corporation's
common stock.
B. The provisions of Articles One and Four of the Plan shall
apply to the Discretionary Option Grant Program and the Automatic Option Grant
Program and shall accordingly govern the interests of all individuals in the
Plan.
III. ADMINISTRATION OF THE PLAN
A. Article Two of the Plan shall be administered by a committee
("Committee") of two (2) or more non-employee Board members appointed by the
Board. Members of the Committee shall serve for such period of time as the Board
may determine and shall be subject to removal by the Board at any time.
B. The Committee which shall act as Plan Administrator (the "Plan
Administrator") shall have full power and authority (subject to the express
provisions of the Plan) to establish such rules and regulations as it may deem
appropriate for the proper administration of the Discretionary Option Grant
Program and to make such determinations and interpretations concerning such
program and any outstanding option under Article Two as it may deem necessary or
advisable. Decisions of the Plan Administrator shall be final and binding on all
parties with an interest in any outstanding option under the Plan.
C. Administration of the Automatic Option Grant Program shall be
self-executing in accordance with the express terms and conditions of Article
Three.
2.
30
IV. ELIGIBILITY FOR OPTION GRANTS
A. The persons eligible to participate under Article Two of
the Plan shall be limited to the following:
(i) officers and other employees of the Corporation
(or its parent or subsidiary corporations) who render services which
contribute to the management, growth and financial success of the
Corporation (or any parent or subsidiary corporation);
(ii) non-employee members of the Board or the
non-employee members of the board of directors of any parent or
subsidiary corporation:
(iii) those consultants or independent contractors who
provide valuable services to the Corporation (or any parent or
subsidiary corporation).
B. Non-employee members of the Board shall also be eligible to
receive automatic option grants pursuant to the provisions of Article Three
(such individuals shall, for purposes of Articles Three and Four, be referred to
as "Eligible Directors").
C. The Plan Administrator shall have full authority to determine
which eligible individuals are to receive discretionary option grants under
Article Two, the number of shares to be covered by each such grant, whether the
granted option is to be an incentive stock option ("Incentive Option") which
satisfies the requirements of Section 422 of the Internal Revenue Code or a
non-statutory option not intended to meet such requirements, the time or times
at which each such option is to become exercisable, and the maximum term for
which the option is to remain outstanding.
V. STOCK SUBJECT TO THE PLAN
A. Shares of the Corporation's common stock, par value $0.01 per
share ("Common Stock") shall be available for issuance under the Plan and shall
be drawn from either the Corporation's authorized but unissued shares of Common
Stock or from reacquired shares of Common Stock, including shares repurchased by
the Corporation on the open market. The aggregate number of shares available for
issuance under the Plan from and after the Effective Date shall not exceed
[2,754,374] shares of Common Stock, subject to adjustment from time to time in
accordance with the provisions of this Section V. Such share reserve includes
(i) the initial number of shares reserved for issuance under the Plan on the
Effective Date, including the shares reserved for issuance under outstanding
options granted under the 1989 Plan and incorporated into this Plan, (ii) the
500,000-share increase authorized by the Board on March 29, 1994 and approved by
the stockholders on May 31, 1994, (iii) an additional 500,000-share
3.
31
increase authorized by the Board on March 17, 1997 and approved by the
stockholders on June 2, 1997, (iv) the [______________]-share increase by the
Board on [ ], subject to stockholder approval at the 1998 Annual Meeting and (v)
the 265,521 share increase effected on January 2, 1998 pursuant to the automatic
annual share increase provisions of the Plan. To the extent one or more
outstanding options under the 1989 Plan which have been incorporated into this
Plan are subsequently exercised, the number of shares issued with respect to
each such option shall reduce, on a share-for-share basis, the number of shares
available for issuance under this Plan.
B. The number of shares of Common Stock available for issuance
under the Plan shall automatically increase on the first day of January each
calendar year, beginning with the 1998 calendar year, by an amount equal to two
percent (2%) of the total number of shares of the Corporation's Common Stock
outstanding on December 31st of the immediately preceding calendar year. All
options granted on the basis of each such annual share increase shall be
non-statutory options under the federal tax laws.
C. The maximum number of shares of Common Stock for which any one
participant in the Plan may be granted stock options and separately exercisable
stock appreciation rights over the term of the Plan shall be limited to 850,000
shares, subject to adjustment from time to time in accordance with the
provisions of this Section V. For purposes of the foregoing limitation, stock
options and stock appreciation rights granted prior to January 1, 1994 shall not
be taken into account.
D. Should one or more outstanding options under this Plan
(including any outstanding options under the 1989 Plan incorporated into this
Plan) expire or terminate for any reason prior to exercise in full (including
any option cancelled in accordance with the cancellation-regrant provisions of
Section IV of Article Two of the Plan), the shares subject to the portion of the
option not so exercised shall be available for subsequent option grant under the
Plan. Shares subject to any option or portion thereof surrendered or cancelled
in accordance with Section V of Article Two and Section III of Article Three of
the Plan shall not be available for subsequent option grant under the Plan.
Should the exercise price of an outstanding option under the Plan (including any
option incorporated from the 1989 Plan) be paid with shares of Common Stock or
should shares of Common Stock otherwise issuable under the Plan be withheld by
the Corporation in satisfaction of the withholding taxes incurred in connection
with the exercise of an outstanding option under the Plan, then the number of
shares available for issuance under the Plan shall be reduced by the gross
number of shares for which the option is exercised, and not by the net number of
shares of Common Stock issued to the option holder.
4.
32
E. In the event any change is made to the Common Stock issuable
under the Plan by reason of any stock split, stock dividend, recapitalization,
combination of shares, exchange of shares or other change affecting the
outstanding Common Stock as a class without receipt of consideration, then
appropriate adjustments shall be made to (i) the maximum number and/or class of
securities issuable under the Plan, (ii) the maximum number and/or class of
securities issuable for which any one individual may be granted stock options
and separately exercisable stock appreciation rights under the Plan after
December 31, 1993, (iii) the number and/or class of securities for which stock
options are to be granted to newly-elected or continuing non-employee Board
members under the Automatic Option Grant Program and (iv) the number and/or
class of securities and price per share in effect under each outstanding option
under the Plan (including each outstanding option incorporated into this Plan
from the 1989 Plan). The purpose of such adjustments to the outstanding options
shall be to preclude the enlargement or dilution of rights and benefits under
those options. The adjustments determined by the Plan Administrator shall be
final, binding and conclusive.
5.
33
ARTICLE TWO
DISCRETIONARY OPTION GRANT PROGRAM
I. TERMS AND CONDITIONS OF OPTIONS
Options granted pursuant to this Article Two shall be authorized
by action of the Plan Administrator and may, at the Plan Administrator's
discretion, be either Incentive Options or non-statutory options. Individuals
who are not Employees may only be granted non-statutory options. Each option
granted shall be evidenced by one or more instruments in the form approved by
the Plan Administrator. Each such instrument shall, however, comply with the
terms and conditions specified below, and each instrument evidencing an
Incentive Option shall, in addition, be subject to the applicable provisions of
Section II of this Article Two.
A. Option Price.
1. The option price per share shall be fixed by the Plan
Administrator, but in no event shall the option price per share be less than the
fair market value per share of Common Stock on the date of the option grant.
2. The option price shall become immediately due upon
exercise of the option and, subject to the provisions of Section VI of this
Article Two and the instrument evidencing the grant, shall be payable in one of
the following alternative forms:
- cash or check made payable to the Corporation's order;
- shares of Common Stock held by the optionee for the
requisite period necessary to avoid a charge to the Corporation's
earnings for financial reporting purposes and valued at fair market
value on the Exercise Date (as such term is defined below); or
- through a broker-dealer sale and remittance procedure
pursuant to which the optionee shall provide irrevocable instructions
(I) to a designated brokerage firm to effect the immediate sale of the
purchased shares and remit to the Corporation, out of the sale proceeds
available on the settlement date, sufficient funds to cover the
aggregate option price payable for the purchased shares plus all
applicable federal and state income and employment taxes required to be
withheld by the Corporation in connection with such purchase and (II) to
the Corporation to deliver the certificates for the purchased shares
directly to such brokerage firm in order to complete the sale
transaction.
6.
34
For purposes of this Section I.A.2, the Exercise Date
shall be the date on which written notice of the option exercise is delivered to
the Corporation. Except to the extent the sale and remittance procedure is used
in connection with the exercise of the option, payment of the option price for
the purchased shares must accompany such notice.
3. The fair market value per share of Common Stock on any
relevant date under the Plan shall be determined in accordance with the
following provisions:
- If the Common Stock is at the time listed or admitted to
trading on any national stock exchange, then the Fair Market Value shall
be the closing selling price per share of Common Stock on the date in
question on the stock exchange determined by the Plan Administrator to
be the primary market for the Common Stock, as such price is officially
quoted in the composite tape of transactions on such exchange. If there
is no reported sale of Common Stock on such exchange on the date in
question, then the Fair Market Value shall be the closing selling price
on the exchange on the last preceding date for which such quotation
exists.
- If the Common Stock is not at the time listed or
admitted to trading on any national stock exchange but is traded on the
Nasdaq National Market, the Fair Market Value shall be the closing
selling price per share of Common Stock on the date in question, as such
price is reported by the National Association of Securities Dealers on
the Nasdaq National Market or any successor system. If there is no
closing selling price for the Common Stock on the date in question, then
the closing selling price on the last preceding date for which such
quotation exists on the Nasdaq National Market shall be determinative of
Fair Market Value.
B. Term and Exercise of Options.
Each option granted under this Article Two shall be
exercisable at such time or times, during such period, and for such number of
shares as shall be determined by the Plan Administrator and set forth in the
instrument evidencing the option grant. No such option, however, shall have a
maximum term in excess of ten (10) years from the grant date.
C. Limited Transferability of Options. During the lifetime of the
optionee, Incentive Options shall be exercisable only by the optionee and shall
not be assignable or transferable other than by will or by the laws of descent
and distribution following the optionee's death. However, non-statutory options
may, in connection with the optionee's estate plan, be assigned in whole or in
part during the optionee's lifetime to one or more members of the optionee's
immediate family or to a trust established exclusively for one or more such
family members. The assigned portion may only be exercised by the person or
persons who acquire a proprietary interest in the option pursuant to the
assignment. The terms applicable to the assigned
7.
35
portion shall be the same as those in effect for the option immediately prior to
such assignment and shall be set forth in such documents issued to the assignee
as the Plan Administrator may deem appropriate.
D. Termination of Service.
1. Except to the extent otherwise provided pursuant to
Section VII of this Article Two, the following provisions shall govern the
exercise period applicable to any options held by the optionee at the time of
cessation of Service or death.
- Should the optionee cease to remain in Service for any
reason other than death or permanent disability, then the period for
which each outstanding option held by such optionee is to remain
exercisable shall be limited to the three (3)-month period following the
date of such cessation of Service.
- In the event such Service terminates by reason of
permanent disability (as defined in Section 22(e)(3) of the Internal
Revenue Code), then the period for which each outstanding option held by
the optionee is to remain exercisable shall be limited to the twelve
(12)-month period following the date of such cessation of Service.
- Should the optionee die while in Service or during the
three (3)-month period following his or her cessation of Service, then
the period for which each of his or her outstanding options is to remain
exercisable shall be limited to the twelve (12)-month period following
the date of the optionee's cessation of Service. During such limited
period, the option may be exercised by the personal representative of
the optionee's estate or by the person or persons to whom the option is
transferred pursuant to the optionee's will or in accordance with the
laws of descent and distribution.
- Under no circumstances, however, shall any option be
exercisable after the specified expiration date of the option term.
- Each such option shall, during such limited exercise
period, be exercisable for any or all of the shares for which the option
is exercisable on the date of the optionee's cessation of Service. Upon
the expiration of such limited exercise period or (if earlier) upon the
expiration of the option term, the option shall terminate and cease to
be exercisable.
2. The Plan Administrator shall have complete discretion,
exercisable either at the time the option is granted or at any time while the
option remains outstanding, to permit one or more options held by the optionee
under this Article Two to be exercised, during the limited period of
exercisability provided under Section I.D.1 above, not only with respect to the
8.
36
number of shares for which each such option is exercisable at the time of the
optionee's cessation of Service but also with respect to one or more subsequent
installments of purchasable shares for which the option would otherwise have
become exercisable had such cessation of Service not occurred.
- The Plan Administrator shall have full power and
authority to extend the period of time for which any option granted
under this Article Two is to remain exercisable following the optionee's
cessation of Service or death from the limited period in effect under
Section I.D.1 of this Article Two to such greater period of time as the
Plan Administrator shall deem appropriate; provided, however, that in no
event shall such option be exercisable after the specified expiration
date of the option term.
3. For purposes of the foregoing provisions of this
Section I.D (and for all other purposes under the Plan):
- The optionee shall be deemed to remain in the SERVICE of
the Corporation for so long as such individual renders services on a
periodic basis to the Corporation (or any parent or subsidiary
corporation) in the capacity of an Employee, a non-employee member of
the Board or an independent consultant or advisor.
- The optionee shall be considered to be an EMPLOYEE for
so long as such individual remains in the employ of the Corporation or
one or more of its parent or subsidiary corporations, subject to the
control and direction of the employer entity as to the work to be
performed and the manner and method of performance.
E. Stockholder Rights.
An optionee shall have no stockholder rights with respect
to any shares covered by the option until such individual shall have exercised
the option and paid the option price for the purchased shares.
II. INCENTIVE OPTIONS
The terms and conditions specified below shall be applicable to
all Incentive Options granted under this Article Two. Incentive Options may only
be granted to individuals who are Employees. Options which are specifically
designated as "non-statutory" options when issued under the Plan shall not be
subject to such terms and conditions.
9.
37
A. Dollar Limitation. The aggregate fair market value (determined
as of the respective date or dates of grant) of the Common Stock for which one
or more options granted to any Employee under this Plan (or any other option
plan of the Corporation or its parent or subsidiary corporations) may for the
first time become exercisable as incentive stock options under the federal tax
laws during any one calendar year shall not exceed the sum of One Hundred
Thousand Dollars ($100,000). To the extent the Employee holds two or more such
options which become exercisable for the first time in the same calendar year,
the foregoing limitation on the exercisability of such options as incentive
stock options under the federal tax laws shall be applied on the basis of the
order in which such options are granted.
B. 10% Stockholder. If any individual to whom an Incentive Option
is granted is the owner of stock (as determined under Section 424(d) of the
Internal Revenue Code) possessing 10% or more of the total combined voting power
of all classes of stock of the Corporation or any one of its parent or
subsidiary corporations ("10% Stockholder"), then the option price per share
shall not be less than one hundred and ten percent (110%) of the fair market
value per share of Common Stock on the grant date, and the option term shall not
exceed five (5) years measured from the grant date.
Except as modified by the preceding provisions of this Section
II, the provisions of the Plan shall apply to all Incentive Options granted
hereunder.
III. CORPORATE TRANSACTION/CHANGES IN CONTROL
A. In the event of any Corporate Transaction or Change in Control
(as defined below), each option which is at the time outstanding under this
Article Two shall automatically accelerate so that each such option shall,
immediately prior to the specified effective date for the Corporate Transaction
or Change in Control, respectively, become fully exercisable with respect to the
total number of shares of Common Stock at the time subject to such option and
may be exercised for all or any portion of such shares. However, an outstanding
option under this Article Two shall not so accelerate upon a Corporate
Transaction if and to the extent such option is, in connection with the
Corporate Transaction, either to be assumed by the successor corporation or
parent thereof or be replaced with a comparable option to purchase shares of the
capital stock of the successor corporation or parent thereof. The determination
of comparability shall be made by the Plan Administrator, and its determination
shall be final and binding.
B. A "Corporate Transaction" shall mean any of the following
stockholder-approved transactions:
(a) a merger or consolidation in which securities possessing
more than fifty percent (50%) of the total combined voting power of the
Corporation's outstanding securities are transferred to a person or
persons different from the persons holding those securities immediately
prior to such transaction, or
10.
38
(b) the sale, transfer or other disposition of all or
substantially all of the Corporation's assets in complete liquidation or
dissolution of the Corporation.
C. For all purposes under the Plan, a "Change in Control" shall
mean a change in control of the Corporation of a nature that would be required
to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A
promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), whether or not the Corporation is then subject to such reporting
requirement, other than a Corporate Transaction; provided that, without
limitation, a Change in Control shall be deemed to have occurred if:
(i) any individual, partnership, firm, corporation,
association, trust, unincorporated organization or other entity, or any
syndicate or group deemed to be a person under Section 14(d)(2) of the
Exchange Act, is or becomes the "beneficial owner" (as defined in Rule
13d-3 of the General Rules and Regulations under the Exchange Act),
directly or indirectly, of securities of the Corporation representing
forty percent (40%) or more of the combined voting power of the
Corporation's then outstanding securities entitled to vote in the
election of directors of the Corporation, pursuant to a tender or
exchange offer made directly to the Corporation's stockholders which the
Board does not recommend such stockholders to accept; or
(ii) a change in the composition of the Board occurs over any
period of two (2) consecutive years or less such that a majority of the
Board ceases for any reason to be comprised of individuals who either
(A) have been Board members continuously since the beginning of that
period or (B) have been elected or nominated for election as Board
members during such period by a vote of at least three-fourths (3/4) of
the Board members described in clause (A) who were still in office at
the time the Board approved such election or nomination.
D. Upon the consummation of the Corporate Transaction, all
outstanding options under this Article Two shall terminate and cease to be
outstanding, except to the extent assumed by the successor corporation or its
parent company. Any options accelerated in connection with the Change in Control
shall remain fully exercisable until the expiration or sooner termination of the
option term.
E. Each outstanding option under this Article Two which is
assumed in connection with the Corporate Transaction or is otherwise to continue
in effect shall be appropriately adjusted, immediately after such Corporate
Transaction, to apply and pertain to the number and class of securities which
would have been issued to the option holder, in consummation of such Corporate
Transaction, had such person exercised the option immediately prior to such
Corporate Transaction. Appropriate adjustments shall also be made to the option
11.
39
price payable per share, provided the aggregate option price payable for such
securities shall remain the same. In addition, the class and number of
securities available for issuance under the Plan following the consummation of
the Corporate Transaction shall be appropriately adjusted.
F. The grant of options under this Article Two shall in no way
affect the right of the Corporation to adjust, reclassify, reorganize or
otherwise change its capital or business structure or to merge, consolidate,
dissolve, liquidate or sell or transfer all or any part of its business or
assets.
G. The exercisability as incentive stock options under the
federal tax laws of any options accelerated under this Section III in connection
with a Corporate Transaction or Change in Control shall remain subject to the
dollar limitation of Section II of this Article Two. To the extent such dollar
limitation is exceeded, the accelerated option shall be exercisable as a
non-statutory option under the federal tax laws.
IV. CANCELLATION AND REGRANT OF OPTIONS
The Plan Administrator shall have the authority to effect, at any
time and from time to time, with the consent of the affected optionees, the
cancellation of any or all outstanding options under this Article Two and to
grant in substitution new options under the Plan covering the same or different
numbers of shares of Common Stock but having an option price per share not less
than the fair market value of the Common Stock on the new grant date (or one
hundred ten percent (110%) of such fair market value in the case of an Incentive
Option granted to a 10% Stockholder).
V. STOCK APPRECIATION RIGHTS
A. Each officer of the Corporation subject to the short-swing
profit restrictions of the federal securities laws shall be granted limited
stock appreciation rights in tandem with his or her outstanding options under
this Article Two. Upon the occurrence of a Hostile Take-Over, each outstanding
option with such a limited stock appreciation right shall automatically be
cancelled, and the optionee shall in return be entitled to a cash distribution
from the Corporation in an amount equal to the excess of (i) the Take-Over Price
of the shares of Common Stock at the time subject to the cancelled option
(whether or not the option is otherwise at the time exercisable for those
shares) over (ii) the aggregate exercise price payable for such shares. The cash
distribution payable upon such cancellation shall be made within five (5) days
following the consummation of the Hostile Take-Over. The Plan Administrator
shall pre-approve, at the time the limited stock appreciation right is granted,
the subsequent exercise of that right in accordance with the terms of the grant
and the provisions of this Section V.A. No additional approval of the Plan
Administrator or the Board shall be required at the time of the actual option
cancellation and cash distribution.
12.
40
B. For purposes of Section V.A, the following definitions shall
be in effect:
A Hostile Take-Over shall be deemed to occur in the event any
person or related group of persons (other than the Corporation or a person that
directly or indirectly controls, is controlled by, or is under common control
with, the Corporation) directly or indirectly acquires beneficial ownership
(within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing
more than fifty percent (50%) of the total combined voting power of the
Corporation's outstanding securities pursuant to a tender or exchange offer
which the Board does not recommend the Corporation's stockholders to accept.
The Take-Over Price per share shall be deemed to be equal to
the greater of (a) the fair market value per share on the date of cancellation,
as determined pursuant to the valuation provisions of Section I.A.3 of this
Article Two, or (b) the highest reported price per share paid in effecting such
Hostile Take-Over. However, if the cancelled option is an Incentive Option, the
Take-Over Price shall not exceed the clause (a) price per share.
C. The shares of Common Stock subject to any option surrendered
or cancelled for an appreciation distribution pursuant to this Section V shall
NOT be available for subsequent option grants under the Plan.
VI. LOANS OR INSTALLMENT PAYMENTS
The Plan Administrator may assist any optionee (including any
officer) in the exercise of one or more outstanding options under this Article
Two, including the satisfaction of any federal and state income and employment
tax obligations arising therefrom, by (a) authorizing the extension of a loan to
such optionee from the Corporation or (b) permitting the optionee to pay the
option price for the purchased Common Stock in installments over a period of
years. The terms of any loan or installment method of payment (including the
interest rate and terms of repayment) will be established by the Plan
Administrator in its sole discretion. Loans and installment payments may be
granted with or without security or collateral (other than to optionees who are
consultants or independent contractors, in which event the loan must be
adequately secured by collateral other than the purchased shares), but the
maximum credit available to the optionee shall not exceed the sum of (i) the
aggregate option price (less par value) of the purchased shares plus (ii) any
federal and state income and employment tax liability incurred by the optionee
in connection with the exercise of the option.
13.
41
ARTICLE THREE
AUTOMATIC OPTION GRANT PROGRAM
I. ELIGIBILITY
The individuals eligible to receive automatic option grants
pursuant to the provisions of this Article Three shall be limited to (i) those
individuals who are first elected or appointed as non-employee Board members on
or after the Effective Date, whether through appointment by the Board or
election by the Corporation's stockholders, provided they have not otherwise
been in the prior employ of the Corporation (or any parent or subsidiary
corporation) and (ii) those individuals who continue to serve as non-employee
Board members on one or more automatic annual option grant dates below while
this Automatic Grant Program remains in effect.
II. TERMS AND CONDITIONS OF AUTOMATIC OPTION GRANTS
A. Grant Dates. Option grants will be made under this Article
Three on the dates specified below. However, the grants specified in
subparagraphs (ii) and (iii) below shall be subject to stockholder approval of
this December 15, 1997 restatement at the 1998 Annual Meeting.
(i) Each individual who first becomes a non-employee
Board member at any time after October 25, 1993, whether through
election at an Annual Stockholders Meeting or through appointment by the
Board, and who has not previously been in the employ of the Corporation
(or any parent or subsidiary corporation) shall automatically be granted
upon the terms and conditions of this Article Three, at the time of such
initial election or appointment, a non-statutory stock option to
purchase 10,000 shares of Common Stock. A non-employee Board member who
replaces a Board member shall not receive an initial 10,000-share grant
if both the new and former Board member are affiliated with the same
investment fund or similar entity.
(ii) On December 15, 1997, each individual serving as
a non-employee Board member shall automatically be granted a
non-statutory stock option to purchase 10,000 shares of Common Stock.
(iii) On the date of the first Board meeting in
December each year, beginning December 1998, each individual continuing
to serve as a non-employee Board member shall automatically be granted a
non-statutory stock option to purchase 10,000 shares of Common Stock,
provided such individual did not receive his or her initial option grant
under this Article III within the preceding six (6) months. In the event
there is no Board meeting in December of
14.
42
any year, then the automatic option grant for that year shall be made on
December 15th: If December 15th in any year is not a day on which the
New York Stock Exchange is open for business (a "Trading Day"), then the
grant for that year shall be made on the immediately succeeding Trading
Day.
The 10,000-share limitation applicable to each initial automatic
option grant and each annual automatic option grant per eligible non-employee
Board member shall be subject to periodic adjustment pursuant to the applicable
provisions of paragraph V.E of Article One.
Stockholder approval of this December 15, 1997 restatement of the
Plan shall constitute pre-approval of each option granted on or after that date
pursuant to the provisions of this Article Three and the subsequent exercise of
that option in accordance with the terms and conditions of this Article Three.
B. Exercise Price. The exercise price per share shall be equal to
one hundred percent (100%) of the Fair Market Value per share of Common Stock on
the automatic grant date.
C. Payment. The option price shall become immediately due upon
exercise of the option and shall be payable in one of the alternative forms
specified in Section I.A.2 of Article Two.
D. Option Term. Each automatic grant under this Article Three
shall have a maximum term of ten (10) years measured from the automatic grant
date.
E. Exercisability. Each automatic option grant under this Article
Three shall become exercisable for the option shares one (1) year after the date
of grant, provided the optionee remains a member of the Board through such date.
Each such option shall remain exercisable until the expiration or sooner
termination of the option term.
F. Limited Transferability. Each automatic grant under this
Article Three may, in connection with the optionee's estate plan, be assigned in
whole or in part during the optionee's lifetime to one or more members of the
optionee's immediate family or to a trust established exclusively for one or
more such family members. The assigned portion may only be exercised by the
person or persons who acquire a proprietary interest in the option pursuant to
the assignment. The terms applicable to the assigned portion shall be the same
as those in effect for the option immediately prior to such assignment.
G. Effect of Termination of Board Membership.
1. Should the optionee cease to be a Board member for any
reason (other than death or Permanent Disability (as defined in Code Section
22(e)(3)) while holding an automatic option grant under this Article Three, then
he or she shall have a three (3)-month
15.
43
period following the date of such cessation of Board membership in which to
exercise such option for any or all of the shares of Common Stock for which the
option is exercisable at the time the optionee ceases service as a Board member.
2. Should the optionee cease to be a Board member by reason of
Permanent Disability while holding an automatic option grant under this Article
Three, then he or she shall have a six (6)-month period following the date of
such cessation of Board membership in which to exercise such option for any or
all of the shares of Common Stock for which the option is exercisable at the
time the optionee ceases service as a Board member.
3. Should the optionee die while serving as a Board member or
during the three (3)-month period following his or her cessation of Board
service, then the option may subsequently be exercised, for any or all of the
shares of Common Stock for which the option is exercisable at the time of the
optionee's cessation of Board membership, by the personal representative of his
or her estate or by the person or persons to whom the option is transferred
pursuant to the Eligible Director's will or in accordance with the laws of
descent and distribution. Any such exercise must, however, occur within six (6)
months after the date of the Eligible Director's death.
4. In no event shall any automatic grant under this Article
Three remain exercisable after the specified expiration date of the ten
(10)-year option term. Upon the expiration of the applicable exercise period in
accordance with subparagraphs 1, 2 and 3 above or (if earlier) upon the
expiration of the ten (10)-year option term, the automatic grant shall terminate
and cease to be exercisable.
H. Stockholder Rights. The holder of an automatic option grant
under this Article Three shall have no stockholder rights with respect to any
shares covered by such option until such individual shall have exercised the
option and paid the exercise price for the purchased shares.
I. Remaining Terms. The remaining terms and conditions of each
automatic option grant shall be as set forth in the prototype Director Automatic
Grant Agreement attached as Exhibit A to the Plan.
III. CORPORATE TRANSACTION/CHANGE IN CONTROL/HOSTILE
TAKEOVER
A. Each automatic option grant outstanding at the time of a
Corporate Transaction or a Change in Control shall automatically accelerate so
that each such option shall, immediately prior to the specified effective date
for such Corporate Transaction or Change in Control, become fully exercisable
with respect to the total number of shares of Common Stock at the time subject
to such option and may be exercised for all or any portion of such shares at any
time prior to the expiration or sooner termination of the option term. Upon the
16.
44
consummation of the Corporate Transaction, all automatic option grants under
this Article Three shall terminate and cease to be outstanding.
B. Upon the occurrence of a Hostile Take-Over, each outstanding
automatic option grant made pursuant to the provisions of this Article Three
shall automatically be cancelled and the optionee shall in return be entitled to
a cash distribution from the Corporation calculated in accordance with Section
V.B of Article Two and payable at the time and in the manner set forth in
Section V.B of Article Two. Stockholder approval of this December 15, 1997
restatement of the Plan shall constitute pre-approval of each option
subsequently granted under this Article Three with such a cancellation provision
and the subsequent cancellation of that option in accordance with the terms of
this Section III.B. No additional approval of the Board or any Plan
Administrator shall be required at the time of the actual option cancellation
and cash distribution.
C. The automatic option grants outstanding under this Article
Three shall in no way affect the right of the Corporation to adjust, reclassify,
reorganize or otherwise change its capital or business structure or to merge,
consolidate, dissolve, liquidate or sell or transfer all or any part of its
business or assets.
D. The shares of Common Stock subject to each option cancelled in
connection with the Hostile Take-Over shall NOT be available for subsequent
issuance under this Plan.
17.
45
ARTICLE FOUR
MISCELLANEOUS
I. AMENDMENT OF THE PLAN
The Board shall have complete and exclusive power and authority
to amend or modify the Plan in any or all respects whatsoever. However, no such
amendment or modification shall, without the consent of the holders, adversely
affect rights and obligations with respect to options at the time outstanding
under the Plan. In addition, certain amendments may require stockholder approval
pursuant to applicable laws or regulations.
II. TAX WITHHOLDING
A. The Corporation's obligation to deliver shares or cash upon
the exercise of stock options or stock appreciation rights granted under the
Plan shall be subject to the satisfaction of all applicable federal, state and
local income and employment tax withholding requirements.
B. The Plan Administrator may, in its discretion and upon such
terms and conditions as it may deem appropriate (including the applicable
safe-harbor provisions of Rule 16b-3 of the Exchange Act) provide any or all
holders of outstanding option grants under Article Two with the election to have
the Corporation withhold, from the shares of Common Stock otherwise issuable
upon the exercise of such options, one or more of such shares with an aggregate
fair market value equal to the designated percentage (any multiple of 5%
specified by the optionee) of the federal and state income and employment taxes
("Taxes") incurred in connection with the acquisition of such shares. In lieu of
such direct withholding, one or more optionees may also be granted the right to
deliver shares of Common Stock to the Corporation in satisfaction of such Taxes.
The withheld or delivered shares shall be valued at the Fair Market Value on the
applicable determination date for such Taxes.
III. EFFECTIVE DATE AND TERM OF PLAN
A. This Plan, as successor to the Corporation's 1989 Plan, became
effective as of the October 25, 1993 Effective Date. The Plan was subsequently
amended and restated by the Board on December 15, 1993 with the purpose of,
among other provisions, deleting direct stock issuances and renaming the Plan to
the 1994 Stock Option Plan. On March 29, 1994 the Board amended and restated the
Plan (the "1994 Restatement") to increase the number of shares of Common Stock
issuable thereunder by 500,000 shares and to impose a limitation on the maximum
number of shares of Common Stock for which any one participant in the Plan may
be granted stock options and separately exercisable stock appreciation rights
after December 31, 1993. The 1994 Restatement was approved by the Corporation's
stockholders in May 1994. On March 17, 1997, the Board adopted amendments to the
Plan (the "1997 Restatement") to effect
18.
46
the following changes: (i) increase the maximum number of shares of Common Stock
available for issuance over the term of the Plan by an additional 500,000
shares; (ii) implement an automatic share increase feature pursuant to which the
number of shares of Common Stock available for issuance under the Plan will
automatically increase on the first day of January each year, beginning January
1, 1998, by two percent (2%) of the total number of shares of Common Stock
outstanding on the last day of December in the immediately preceding year; (iii)
increase the maximum number of shares available for issuance under the Automatic
Option Grant Program in effect under the Plan by an additional 33,334 shares to
150,000 shares; (iv) impose a specific limitation of 850,000 shares on the
maximum number of shares for which any one participant may be granted stock
options and separately exercisable stock appreciation rights in the aggregate
under the 1994 Plan; (v) render the non-employee Board members eligible to
receive option grants under the Discretionary Option Grant Program; (vi) remove
certain restrictions on the eligibility of non-employee Board members to serve
as Plan Administrator; and(vii) effect a series of additional changes to the
provisions of the Plan (including the stockholder approval requirements, the
transferability of non-statutory stock options and the elimination of the six
(6)-month holding period requirement as a condition to the exercise of stock
appreciation rights) in order to take advantage of the recent amendments to Rule
16b-3 of the Securities and Exchange Commission which exempts certain officer
and director transactions under the 1993 Plan from the short-swing liability
provisions of the federal securities laws. The 1997 Restatement was approved by
the Corporation's stockholders on June 2, 1997.
B. On December 15, 1997, the Board adopted a series of amendments
(the "1997 Amendment") to the Plan which increase the maximum number of shares
of Common Stock issuable thereunder by an additional ________ shares and effect
the following changes to the Automatic Option Grant Program for non-employee
Board members under Article Three of the Plan: (i) increase the number of shares
of Common Stock for which options are to be granted annually (the "Annual
Automatic Grant") to each non-employee Board member from five thousand (5,000)
shares to ten thousand (10,000) shares; (ii) change the date on which such
Annual Automatic Grants are to be made to the non-employee Board members from
the date of the Annual Stockholders Meeting to the date of the first Board
meeting in December each year (commencing December 1997); provided, however,
that if there is no Board meeting in December of any year, the Annual Automatic
Grants for that year shall be made on December 15 or, if December 15th is not a
Trading Day, the immediately succeeding Trading Day; (iii) authorize and effect
an Annual Automatic Grant for each individual serving as a non-employee Board
member on December 15, 1997, whether or not that individual received his or her
initial automatic grant within the preceding six (6) months; (iv) provide that
after December 15, 1997, each non-employee Board member shall be eligible to
receive an Automatic Option Grant in December of any year only if that
individual did not receive his or her initial automatic grant within the
preceding six (6) months; and (v) eliminate the provisions of the Plan which
impose a 150,000-share limitation on the maximum number of shares issuable under
the Automatic Option Grant Program. The 1997 Amendment is subject to stockholder
approval at the 1998 Annual Meeting, and no Annual Automatic Grant or any other
option grant which is based on the ________-share increase effected by the 1997
Amendment shall become exercisable in
19.
47
whole or in part unless and until the 1997 Amendment is so approved. Should such
stockholder approval not be obtained at the 1998 Annual Meeting, then each
outstanding Annual Automatic Grant shall terminate and cease to remain
outstanding, and any option grants based on the __________-share increase shall
terminate and no further option grants shall be made on the basis of that
increase. However, the provisions of the Plan, including the Automatic Option
Grant Program, as in effect immediately prior to the 1997 Amendment shall
automatically be reinstated, and option grants may thereafter continue to be
made pursuant to the reinstated provisions of the Plan and the Automatic Option
Grant Program. All option grants made prior to the 1997 Amendment shall remain
outstanding in accordance with the terms and conditions of the respective
instruments evidencing those options, and nothing in the 1997 Amendment shall be
deemed to modify or in any way affect those outstanding options.
C. Each option issued and outstanding under the 1989 Plan
immediately prior to the Effective Date shall be incorporated into this Plan and
treated as an outstanding option under this Plan, but each such option shall
continue to be governed solely by the terms and conditions of the instrument
evidencing such grant, and nothing in this Plan shall be deemed to affect or
otherwise modify the rights or obligations of the holders of such options with
respect to their acquisition of shares of Common Stock thereunder or their
exercise of outstanding stock appreciation rights thereunder.
D. The Plan shall terminate upon the earlier of (i) July 27, 2003
or (ii) the date on which all shares available for issuance under the Plan have
been issued pursuant to the exercise of options granted under Article Two. If
the date of termination is determined under clause (i) above, then no options
outstanding on such date shall be affected by the termination of the Plan, and
such securities shall thereafter continue to have force and effect in accordance
with the provisions of the instruments evidencing such options.
E. Options may be granted under this Plan to purchase shares of
Common Stock in excess of the number of shares then available for issuance under
the Plan, provided each option granted is not to become exercisable, in whole or
in part, at any time prior to stockholder approval of an amendment authorizing a
sufficient increase in the number of shares issuable under the Plan.
IV. REGULATORY APPROVALS
A. The implementation of the Plan, the granting of any option
hereunder, and the issuance of stock upon the exercise or surrender of any such
option shall be subject to the procurement by the Corporation of all approvals
and permits required by regulatory authorities having jurisdiction over the
Plan, the options granted under it and the stock issued pursuant to it.
20.
48
B. No shares of Common Stock or other assets shall be issued or
delivered under the Plan unless and until there shall have been compliance with
all applicable requirements of federal and state securities laws, including the
filing and effectiveness of a Form S-8 registration statement for the shares of
Common Stock issuable under the Plan, and all applicable listing requirements of
any securities exchange on which stock of the same class is then listed.
V. USE OF PROCEEDS
Any cash proceeds received by the Corporation from the sale of
shares pursuant to options granted under the Plan shall be used for general
corporate purposes.
VI. NO EMPLOYMENT/SERVICE RIGHTS
Neither the action of the Corporation in establishing the Plan,
nor any action taken by the Plan Administrator hereunder, nor any provision of
the Plan shall be construed so as to grant any individual the right to remain in
the employ or Service of the Corporation (or any parent or subsidiary
corporation) for any period of specific duration, and the Corporation (or any
parent or subsidiary corporation retaining the services of such individual) may
terminate such individual's employment or Service at any time and for any
reason, with or without cause.
VII. MISCELLANEOUS PROVISIONS
A. The right to acquire Common Stock or other assets under the
Plan may not be assigned, encumbered or otherwise transferred by any optionee.
B. The provisions of the Plan shall be governed by the laws of
the state of California, as such laws are applied to contracts entered into and
performed in such state.
C. The provisions of the Plan shall inure to the benefit of, and
be binding upon, the Corporation and its successors or assigns, whether by
Corporate Transaction or otherwise, and the optionees, the legal representatives
of their respective estates, their respective heirs or legatees and their
permitted assignees.
21.
49
EXHIBIT A
Director Automatic Grant Agreement
50
INSITE VISION INCORPORATED
1994 STOCK OPTION PLAN
NON-EMPLOYEE DIRECTOR OPTION AGREEMENT
RECITALS
A. Under the Automatic Option Grant Program in effect under the
Corporation's 1994 Stock Option Plan (the "Plan"), the non-employee members of
the Corporation's Board of Directors (the "Board") will automatically receive
periodic option grants designed to reward them for services they have rendered
to the Corporation and to encourage them to continue in the service of the
Corporation.
B. Optionee is a non-employee member of the Board, and this
Agreement is executed pursuant to, and is intended to carry out the purposes of,
the Plan in connection with the automatic grant on this day of a stock option to
purchase shares of the Corporation's common stock ("Common Stock") under Article
Three of the Plan.
C. The granted option is intended to be a non-statutory option
which does not meet the requirements of Section 422 of the Internal Revenue
Code.
NOW, THEREFORE, it is hereby agreed as follows:
1. GRANT OF OPTION. Subject to and upon the terms and conditions
set forth in this Agreement, the Corporation hereby grants to Optionee, as of
the automatic grant date (the "Grant Date") specified in the accompanying Notice
of Automatic Option Grant (the "Grant Notice"), a stock option to purchase up to
that number of shares of Common Stock (the "Option Shares") as is specified in
the Grant Notice. The Option Shares shall be purchasable from time to time
during the option term at the option price per share (the "Option Price")
specified in the Grant Notice, which is one hundred percent (100%) of the fair
market value of the Common Stock on the Grant Date.
2. OPTION TERM. This option shall have a term of ten (10) years
measured from the Grant Date and shall accordingly expire at the close of
business on the expiration date specified in the Grant Notice ("Expiration
Date"), unless sooner terminated in accordance with Paragraph 5 or 6.
3. LIMITED TRANSFERABILITY. This option may, in connection with
the Optionee's estate plan, be assigned in whole or in part during the
Optionee's lifetime to one or more members of the Optionee's immediate family or
to a trust established exclusively for one or more such family members. The
assigned portion may only be exercised by the person or
51
persons who acquire a proprietary interest in the option pursuant to the
assignment. The terms applicable to the assigned portion shall be the same as
those in effect for the option immediately prior to such assignment and shall be
set forth in such documents issued to the assignee as the Plan Administrator may
deem appropriate.
4. EXERCISABILITY. This option shall become exercisable for the
Option Shares one (1) year after the Grant Date, provided Optionee remains in
Board service through such date. This option shall thereafter remain so
exercisable until the expiration or sooner termination of the option term.
5. CESSATION OF BOARD SERVICE. Should Optionee's service as a
Board member cease while this option remains outstanding, then the option term
specified in Paragraph 2 shall terminate (and this option shall cease to be
exercisable) prior to the Expiration Date in accordance with the following
provisions:
(i) This option shall immediately terminate and cease to be
outstanding for any Option Shares for which the option is not
exercisable at the time of Optionee's cessation of Board service.
(ii) Should Optionee cease Board service (for any reason other
than Permanent Disability or death) while this option remains
outstanding, then the period for exercising this option shall be reduced
to a three (3)-month period commencing with the date of such cessation
of Board service. During such limited period of exercisability, this
option may not be exercised for more than the number of Option Shares
(if any) for which it is exercisable on the date of Optionee's cessation
of Board service. Upon the expiration of such three (3)-month period or
(if earlier) upon the Expiration Date, this option shall terminate and
cease to be exercisable.
(iii) Should Optionee cease Board service by reason of
Permanent Disability while this option is outstanding, then Optionee
shall have a period of six (6) months (commencing with the date of such
cessation of Board service) during which to exercise this option for any
or all of the Option Shares for which this option is exercisable at the
time of Optionee's cessation of Board service. Upon the expiration of
such six (6)-month period or (if earlier) upon the Expiration Date, this
option shall terminate and cease to be exercisable. "Permanent
Disability" shall mean the inability to engage in any substantial
gainful activity by reason of any medically determinable physical or
mental impairment which can be expected to result in death or which has
lasted or can be expected to last for a continuous period of not less
than twelve (12) months.
(iv) Should Optionee die while serving as a Board member or
during the three (3)-month period following Optionee's cessation of
Board service,
2.
52
then the personal representative of Optionee's estate or the person or
persons to whom this option is transferred pursuant to Optionee's will
or in accordance with the laws of descent and distribution shall have
the right to exercise the option for any or all of the Option Shares for
which this option is exercisable at the time of Optionee's cessation of
Board service (less any Option Shares subsequently purchased by Optionee
prior to death). Such right shall lapse, and this option shall terminate
and cease to remain outstanding, upon the earlier of (A) the expiration
of the six (6)-month period measured from the date of Optionee's death
or (B) the Expiration Date.
6. ADJUSTMENT IN OPTION SHARES. In the event any change is made
to the Common Stock issuable under the Plan by reason of any stock split, stock
dividend, recapitalization, combination of shares, exchange of shares, or other
change affecting the outstanding Common Stock as a class without receipt of
consideration, then appropriate adjustments shall be made to (i) the total
number and/or class of Option Shares subject to this option and (ii) the Option
Price payable per share in order to reflect such change and thereby preclude the
dilution or enlargement of Optionee's rights and benefits hereunder.
7. SPECIAL ACCELERATION OF OPTION.
A. In the event of any of the following stockholder-approved
transactions (a "Corporate Transaction"):
(i) a merger or consolidation in which securities possessing
more than fifty percent (50%) of the total combined voting power of the
Corporation's outstanding securities are transferred to a person or
persons different from those who held those securities immediately prior
to such transaction, or
(ii) the sale, transfer or other disposition of all or
substantially all of the Corporation's assets in complete liquidation or
dissolution of the Corporation,
this option shall, to the extent the option is at such time
outstanding but not otherwise fully exercisable, automatically accelerate so
that such option shall, immediately prior to the specified effective date for
the Corporate Transaction, become fully exercisable for all of the Option Shares
and may be exercised for all or any portion of such shares.
B. This option, to the extent not previously exercised, shall
terminate upon the consummation of the Corporate Transaction and cease to be
outstanding, except to the extent assumed by the successor corporation (or its
parent company) in such Corporate Transaction.
3.
53
C. This Agreement shall not in any way affect the right of the
Corporation to adjust, reclassify, reorganize or otherwise make changes in its
capital or business structure or to merge, consolidate, dissolve, liquidate or
sell or transfer all or any part of its business or assets.
8. CHANGE IN CONTROL/HOSTILE TAKE-OVER.
A. In the event of any Change in Control (as defined below), the
exercisability of this option shall automatically accelerate so that the option
shall, immediately prior to the specified effective date for the Change in
Control, become fully exercisable for all of the Option Shares at the time
subject to this option and may be exercised for all or any portion of the Option
Shares at any time prior to the expiration or sooner termination of the option
term.
B. For all purposes under the Plan, a Change in Control shall mean
a change in control of the Corporation of a nature that would be required to be
reported in response to Item 6(e) of Schedule 14A of Regulation 14A promulgated
under the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
whether or not the Corporation is then subject to such reporting requirement;
provided that, without limitation, a Change in Control shall be deemed to have
occurred if:
(i) any individual, partnership, firm, corporation,
association, trust, unincorporated organization or other entity,
or any syndicate or group deemed to be a person under Section
14(d)(2) of the Exchange Act, is or becomes the "beneficial
owner" (as defined in Rule 13d-3 of the General Rules and
Regulations under the Exchange Act), directly or indirectly, of
securities of the Corporation representing forty percent (40%) or
more of the combined voting power of the Corporation's then
outstanding securities entitled to vote in the election of
directors of the Corporation, pursuant to a tender or exchange
offer made directly to the Corporation's stockholders which the
Board does not recommend such stockholders to accept; or
(ii) a change in the composition of the Board occurs over any
period of two (2) consecutive years or less such that a majority
of the Board ceases for any reason to be comprised of individuals
who either (A) have been Board members continuously since the
beginning of that period or (B) have been elected or nominated
for election as Board members during such period by a vote of at
least three-fourths (3/4) of the Board members described in
clause (A) who were still in office at the time the Board
approved such election or nomination.
C. In the event there should occur a Hostile Take-Over (as defined
below), then this option shall be automatically cancelled on the fifth (5th)
business day following such Hostile Take-Over in exchange for a cash
distribution from the Corporation in an amount equal
4.
54
to the excess of (I) the Take-Over Price of all the Option Shares at the time
subject to the cancelled option, over (II) the aggregate Option Price payable
for such shares. Stockholder approval of the December 15, 1997 restatement of
the Plan at the 1998 Annual Meeting shall constitute pre-approval of the
cancellation of this option in accordance with the terms of this Paragraph 8.C.
No additional approval of the Board or any Plan Administrator shall be required
at the time of the actual option cancellation and cash distribution.
D. Definitions:
A "Hostile Take-Over" shall be deemed to occur in the
event any person or related group of persons (other than the Corporation
or a person that directly or indirectly controls, is controlled by or is
under common control with, the Corporation) directly or indirectly
acquires beneficial ownership (within the meaning of Rule 13d-3 of the
Exchange Act) of securities possessing more than fifty percent (50%) of
the total combined voting power of the Corporation's outstanding
securities pursuant to a tender or exchange offer which the Board does
not recommend the Corporation's stockholders to accept.
The "Take-Over Price" per share shall be deemed to be
equal to the greater of (a) the Fair Market Value per share on the date
of cancellation (as determined in accordance with the provisions of
Paragraph 9.B below) or (b) the highest reported price per share paid in
effecting such Hostile Take-Over.
E. This Agreement shall in no way affect the right of the
Corporation to adjust, reclassify, reorganize or otherwise change its capital or
business structure or to merge, consolidate, dissolve, liquidate or sell or
transfer all or any part of its business or assets.
9. MANNER OF EXERCISING OPTION.
A. In order to exercise this option with respect to all or any
part of the Option Shares for which this option is at the time exercisable,
Optionee (or in the case of exercise after Optionee's death, Optionee's
executor, administrator, heir or legatee, as the case may be) must take the
following actions:
(i) Execute and deliver to the Secretary of the Corporation a
written notice of exercise in substantially the form of Exhibit I
attached hereto in which there is specified the number of Option Shares
for which the option is exercised.
(ii) Pay the aggregate Option Price for the purchased shares
in one or more of the following alternative forms:
(a) Cash or check made payable to the Corporation's
order;
5.
55
(b) Shares of Common Stock held by Optionee for the
requisite period necessary to avoid a charge to the Corporation's
earnings for financial reporting purposes and valued at Fair Market
Value on the Exercise Date (as such terms are defined below); or
(c) Through a broker-dealer sale and remittance procedure
pursuant to which the Optionee shall provide irrevocable instructions
(I) to a designated brokerage firm to effect the immediate sale of the
purchased shares and remit to the Corporation, out of the sale proceeds
available on the settlement date, sufficient funds to cover the
aggregate Option Price payable for the purchased shares plus all
applicable federal and state income and employment taxes required to be
withheld by the Corporation in connection with such purchase and (II) to
the Corporation to deliver the certificates for the purchased shares
directly to such brokerage firm in order to complete the sale
transaction; or
(iii) Furnish to the Corporation appropriate documentation
that the person or persons exercising the option (if other than
Optionee) have the right to exercise this option.
B. For purposes of this Agreement the Exercise Date shall be the
date on which the Exercise Notice shall have been delivered to the Corporation.
Except to the extent the sale and remittance procedure specified in subparagraph
(ii)(c) of paragraph A above may be utilized to exercise this option, payment of
the Option Price for the purchased shares must accompany such notice. For all
valuation purposes under this Agreement, the Fair Market Value per share of
Common Stock on any relevant date shall be the closing selling price per share
of Common Stock on the date in question on the Nasdaq National Market, as such
price is reported by the National Association of Securities Dealers on the
Nasdaq National Market or any successor system. If there is no closing selling
price on the date in question, then the Fair Market Value shall be the closing
selling price on the last preceding date for which such quotation exists on the
Nasdaq National Market.
C. As soon as practical after the Exercise Date, the Corporation
shall issue to or on behalf of Optionee (or any other person or persons
exercising this option) a certificate or certificates representing the Option
Shares purchased and paid for in accordance herewith.
D. In no event may this option be exercised for any fractional
shares.
10. STOCKHOLDER RIGHTS. The holder of this option shall not have
any of the rights of a stockholder with respect to the Option Shares until such
individual shall have exercised this option, paid the Option Price for the
purchased shares and been issued one or more certificates for the purchased
shares.
6.
56
11. NO IMPAIRMENT OF RIGHTS. Nothing in this Agreement shall be
construed or interpreted so as to affect adversely or otherwise impair the right
of the Corporation or the stockholders to remove Optionee from Board service at
any time in accordance with the provisions of applicable law.
12. COMPLIANCE WITH LAWS AND REGULATIONS.
A. The exercise of this option and the issuance of the Option
Shares upon such exercise shall be subject to compliance by the Corporation and
Optionee with all applicable requirements of law relating thereto and with all
applicable regulations of any stock exchange on which shares of the
Corporation's Common Stock may be listed at the time of such exercise and
issuance.
B. In connection with the exercise of this option, Optionee shall
execute and deliver to the Corporation such representations in writing as may be
requested by the Corporation in order for it to comply with the applicable
requirements of federal and state securities laws.
13. SUCCESSORS AND ASSIGNS. Except to the extent otherwise
provided in Paragraph 3 or 7, the provisions of this Agreement shall inure to
the benefit of, and be binding upon, the successors, administrators, heirs,
legal representatives and assigns of Optionee and the successors and assigns of
the Corporation.
14. LIABILITY OF CORPORATION.
A. If the Option Shares covered by this Agreement exceed, as of
the Grant Date, the number of shares of Common Stock which may without
stockholder approval be issued under the Plan, then this option shall be void
with respect to such excess shares unless stockholder approval of an amendment
sufficiently increasing the number of shares of Common Stock issuable under the
Plan is obtained in accordance with the provisions of Article Four, Section III
of the Plan.
B. The inability of the Corporation to obtain approval from any
regulatory body having authority deemed by the Corporation to be necessary to
the lawful issuance and sale of any Common Stock pursuant to this option shall
relieve the Corporation of any liability with respect to the non-issuance or
sale of the Common Stock as to which such approval shall not have been obtained.
However, the Corporation shall use its best efforts to obtain all such
approvals.
15. NOTICES. Any notice required to be given or delivered to the
Corporation under the terms of this Agreement shall be in writing and addressed
to the Corporation in care of the Corporate Secretary at the Corporate Offices
at 965 Atlantic Avenue, Alameda, California 94501. Any notice required to be
given or delivered to Optionee shall be in writing and addressed to Optionee at
the address indicated below Optionee's signature line on the Grant
7.
57
Notice. All notices shall be deemed to have been given or delivered upon
personal delivery or upon deposit in the U.S. mail, postage prepaid and properly
addressed to the party to be notified.
16. CONSTRUCTION/GOVERNING LAW. This Agreement and the option
evidenced hereby are made and granted pursuant to the Plan and are in all
respects limited by and subject to the express terms and provisions of the Plan.
The interpretation, performance and enforcement of this Agreement shall be
governed by the laws of the State of California without resort to that state's
conflict-of-laws rules.
8.
58
EXHIBIT I
NOTICE OF EXERCISE OF STOCK OPTION
I hereby notify InSite Vision Incorporated (the "Corporation")
that I elect to purchase _____ ( ) shares of the Corporation's Common Stock (the
"Purchased Shares") pursuant to that certain option (the "Option") granted to me
on _______, 199 to purchase up to Ten Thousand (10,000) shares of such Common
Stock at an option price of $_____ per share (the "Option Price").
Concurrently with the delivery of this Exercise Notice to the
Secretary of the Corporation, I shall pay to the Corporation the Option Price
for the Purchased Shares in accordance with the provisions of my agreement with
the Corporation evidencing the Option and shall deliver whatever additional
documents may be required by such agreement as a condition for exercise.
- ------------------------ ------------------------------------
Date Optionee
Address: ------------------------------------
------------------------------------
Print name in exact manner
it is to appear on the
stock certificate:
------------------------------------
------------------------------------
Address to which certificate
is to be sent, if different
from address above:
------------------------------------
------------------------------------
Social Security Number:
59
PROXY INSITE VISION INCORPORATED
965 Atlantic Avenue, Alameda, California 94501
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned revokes all previous proxies, acknowledges receipt of the
Notice of the Annual Meeting of Stockholders and the Proxy Statement and
appoints S. Kumar Chandrasekaran, Ph.D. and Michael D. Baer, and each of them,
the Proxy of the undersigned, with full power of substitution, to vote all
shares of Common Stock of InSite Vision Incorporated (the "Company") held of
record by the undersigned on April 10, 1998, either on his or her own behalf or
on behalf of any entity or entities, at the Annual Meeting of Stockholders of
the Company to be held June 8, 1998, and at any adjournment or postponement
thereof, with the same force and effect as the undersigned might or could do if
personally present thereat. The shares represented by this Proxy shall be voted
in the manner set forth below.
1. To elect the following directors to serve until the 1999 annual meeting of
stockholders or until their respective successors are elected and qualified:
FOR WITHHOLD AUTHORITY TO VOTE
S. Kumar Chandrasekaran, Ph.D. [ ] [ ]
FOR WITHHOLD AUTHORITY TO VOTE
Mitchell H. Friedlaender, M.D. [ ] [ ]
FOR WITHHOLD AUTHORITY TO VOTE
John E. Lucas [ ] [ ]
FOR WITHHOLD AUTHORITY TO VOTE
John L. Mattana [ ] [ ]
FOR WITHHOLD AUTHORITY TO VOTE
Anders P. Wiklund [ ] [ ]
2. To approve a series of amendments to the Company's 1994 Stock Option Plan
(the "1994 Plan"), including (i) revisions to the Automatic Option Grant
Program for non-employee Board members under the 1994 Plan to change the dates
on which grants are to be made under the program and to increase the number of
shares for which such options are to be granted and (ii) elimination of the
150,000-share limitation on the maximum number of shares issuable under the
Automatic Option Grant Program.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
60
3. To ratify and approve the Company's issuance of 7,000 shares of Series A
Convertible Preferred Stock, and a warrant to purchase 70 shares of Series A
Convertible Preferred Stock, in a private placement effective as of September
12, 1997.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
4. To ratify the Board of Directors' selection of Ernst & Young LLP to serve
as the Company's independent accountants for the fiscal year ending December
31, 1998.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
5. To transact such other business as may properly come before the meeting
or any adjournment or postponement thereof.
(PLEASE DATE AND SIGN ON REVERSE SIDE)
This Proxy, when properly executed, will be voted in the manner directed
herein. THIS PROXY WILL BE VOTED FOR THE ELECTION OF THE DIRECTORS LISTED AND
FOR THE OTHER PROPOSALS IF NO SPECIFICATION IS MADE.
Please sign exactly as your name(s) is (are) shown on the stock certificate to
which the Proxy applies. When shares are held by joint tenants, both should
sign. When signing as an attorney, executor, administrator, trustee or
guardian, please give full title, as such. If a corporation, please sign in
full corporate name by the President or other authorized officer. If a
partnership, please sign in the partnership name by an authorized person.
Dated: ,1998
----------------------------
-------------------------------------------
Signature
-------------------------------------------
Signature if held jointly
PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY USING THE ENCLOSED
ENVELOPE.